$GRC Declares #Cash #Dividend

The Board of Directors of The Gorman-Rupp Company (NYSE MKT: GRC) has declared a quarterly cash dividend of $0.105 per share on the common stock of the Company, payable September 9, 2016, to shareholders of record August 15, 2016. This marks the 266^th consecutive quarterly dividend paid by The Gorman-Rupp Company.

Brigette A. Burnell
Corporate Secretary
The Gorman-Rupp Company
Telephone (419) 755-1246
NYSE MKT: GRC

$AVXL Confirms #Phase2a Study of #ANAVEX 2-73 in #Alzheimer’s

NEW YORK, July 29, 2016 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.

Dr. Norman Relkin, MD, PhD, an Alzheimer clinical trialist and an advisor to Anavex, commented:  “To interpret the ANAVEX 2-73 results presented at the 2016 AAIC meeting, it is important to keep in mind the stated goals of this first in Alzheimer’s patients study.  This was a Phase 2a study, primarily designed to determine which ANAVEX 2-73 dosages are safe to administer to mild to moderate stage Alzheimer’s patients.  The study was successful in establishing the maximum tolerated dose and in revealing the range of ANAVEX 2-73 doses that are well-tolerated by Alzheimer patients. It also provided encouraging evidence that previously reported positive trends in certain cognitive and biologic measures persisted over a period of approximately 31 weeks.  However, this analysis was based on pooled data from a relatively small number of subjects receiving a variety of doses.  It is therefore unlikely that these findings reflect the full potential ANAVEX 2-73 in treating Alzheimer’s disease.  It is unreasonable to draw conclusions about any limits to the long-term efficacy of ANAVEX 2-73 based on the interim Phase 2a findings, especially since no statistically significant decline from baseline was reported, which is impressive.  Detailed pre-planned analysis of the pharmacodynamic results is in progress, which is one of the key factors of relevance for regulatory agencies and which will also determine the optimal dose for future studies.“

Anavex confirms that there has been no change with regards to its science, data or the fundamentals of the Company. Anavex remains dedicated to advancing ANAVEX 2-73 and will be reporting new data to investors as it becomes available.

Anavex confirms the data included in its news release dated July 27, 2016.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email:  info@anavex.com

Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com 

Media:
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

$KGJI Sells Jewelry Park for Approximately $171 Million

Company will Focus on Expansion of its Core Jewelry Business; Will Relocate Its Headquarters to the Jewelry Park

WUHAN CITY, China, July 29, 2016 — Kingold Jewelry, Inc. (“Kingold” or “the Company”) (NASDAQ: KGJI), one of China’s leading manufacturers and designers of high quality 24-karat gold jewelry, ornaments and investment-oriented products, today announced that Wuhan Kingold Jewelry Company Limited (“Wuhan Kingold”), the controlled subsidiary of the Company, has sold all of its interest in the Shanghai Creative Industry Park, or the Kingold Jewelry Cultural Industry Park (the “Jewelry Park”) to Wuhan Lianfuda Investment Management Co., Ltd. (“Wuhan Lianfuda”) for RMB 1.14 billion (approximately US$ 171 million). In connection with the sale, Kingold leased space in the Jewelry Park for its new headquarters for an annual rent of RMB 1,718,400 (approximately US$ 256,800).

Wuhan Lianfuda has paid Wuhan Kingold the total consideration of RMB 1.14 billion (approximately US$ 171 million), pursuant to a contract to transfer the contractual rights and obligations (the “Transfer Contract”) entered between Wuhan Kingold and Wuhan Lianfuda. In addition, Kingold transfers and Wuhan Lianfuda receives, all the rights and obligations in an acquisition agreement (the “Acquisition Agreement”) signed among Kingold, Wuhan Wansheng and Wuhan Huayuan Science and Technology Development Limited Company (“Wuhan Huayuan”) on October 23, 2013, including 60% stock rights of Wuhan Huayuan. Wuhan Lianfuda will undertake the remaining payment obligation of RMB 360 million (approximately US$ 54 million) stipulated in the Acquisition Agreement. According to an evaluation report issued by an independent evaluation agency, the evaluated value of the Jewelry Park on June 18, 2016 was approximately RMB 1.48 billion (approximately US$ 221 million).

Background on Development of the Jewelry Park

On October 29, 2013, the Company filed a current report on Form 8-K disclosing the Acquisition Agreement. Pursuant to the Acquisition Agreement as amended, the Company acquired the operating rights for 66,667 square meters (approximately 717,598 square feet, or 16.5 acres) of industrial land for use in the development of the Jewelry Park for approximately RMB 1.0 billion (approximately US$ 150 million) from Wuhan Wansheng, and authorized Wuhan Wansheng, as an agent, to complete construction of the Jewelry Park. Upon completion of the whole project, the Company would have 100% ownership of the properties situated on the land.

Before the Transfer Contract was signed, the project was in the process of final inspection, acceptance and filing for the record. The Company had paid RMB 640 million (approximately US$ 96 million) for the share acquisition fees and the construction fees to Wuhan Wansheng and Wuhan Wansheng had transferred 60% of the stock rights of Wuhan Huayuan to the Company. Wuhan Wansheng and Wuhan Huayuan issued the consent of Jewelry Park transfer to the Company on the day when the Transfer Contract was signed.

Relocation of Kingold’s Headquarters

On June 27, 2016, The Company signed two leases with Wuhan Huayuan to rent certain space at the Jewelry Park as its new headquarter office and store:

i) The Company’s office located in Floor 10, Tower A, Building 7 of the Jewelry Park with 1,200 square meters

ii) The Company’s store will be located in No. 6 store, Building 1 of the Jewelry Park with 340 square meters

The aggregate monthly rent is RMB 143,200 (approximately US$ 21,400) and the aggregate yearly rent is RMB 1,718,400 (approximately US$ 256,800). The Company will relocate its corporate offices to the Jewelry Park in August 2016, and plans to move the store to the Jewelry Park in October 2016. The Company’s current headquarters will be used as a factory.

Management Commentary

Mr. Zhihong Jia, Chairman and CEO of the Company, commented, “We were pleased to complete a transaction that provides Kingold with a positive return on investment on our development in the Jewelry Park.  Ultimately, our management team decided that it was in the best interest of our Company to focus our capital and personal resources towards expanding our core jewelry design and manufacturing business.  We expect to utilize the proceeds to continue to grow both within China and internationally.  We also will be pleased to work with Wuhan Lianfuda as the Jewelry Park develops into what our Company envisioned, a robust market serving as a bridge between upstream and downstream companies within the jewelry industry, and we are excited to be part of this ongoing collective market activity.”

About Kingold Jewelry, Inc.

Kingold Jewelry, Inc. (NASDAQ: KGJI), centrally located in Wuhan City, one of China’s largest cities, was founded in 2002 and today is one of China’s leading designers and manufacturers of 24-karat gold jewelry, ornaments, and investment-oriented products. The Company sells both directly to retailers as well as through major distributors across China. Kingold has received numerous industry awards and has been a member of the Shanghai Gold Exchange since 2003. For more information, please visit www.kingoldjewelry.com.

Business Risks and Forward-Looking Statements

This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. You can identify these forward-looking statements by words such as “expects,” “believe,” “project,” “anticipate,” or similar expressions. The forward-looking statements in this release include statements regarding Kingold’s outlook with respect to its 2016 outlook for gold processing, its expectations with respect to completion of construction of the Jewelry Park and planned grand opening, as well as its ability to engage in presales and finance the remaining construction.  Readers are cautioned that actual results could differ materially from those expressed in any forward-looking statements. Forward-looking statements are subject to a number of risks, including those contained in Kingold’s SEC filings available at www.sec.gov, including Kingold’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Kingold undertakes no obligation to update or revise any forward-looking statements for any reason.

Company Contact
Kingold Jewelry, Inc.
Bin Liu, CFO
Phone: +1-847-660-3498 (US) / +86-27-6569-4977 (China)
bl@kingoldjewelry.com

INVESTOR RELATIONS
The Equity Group Inc.
Katherine Yao, Senior Associate
Phone: +86-10-6587-6435
kyao@equityny.com

$OPCO #Switchgrass #BioChar #Natural #Cat Litter Launches at #SuperZoo

$EXPI #RussCofano Joins eXp World Holdings and eXp Realty

Industry Veteran Named Chief Strategy Officer and General Counsel

$PYDS Launches $AAPL #iOS #PaymentProcessing #SDK

SAN ANTONIO, July 28, 2016  — Payment Data Systems, Inc. (NASDAQ:PYDS), an integrated payments solutions provider, today announced the launch of PDS Checkout for Apple iOS, a software development kit (SDK) that enables mobile apps to easily accept payments using Payment Data Systems’s credit card and ACH processing platforms.

“We’re thrilled to offer the Apple developer community the ability to create better mobile payment experiences for their business clients and, at lower processing rates than many of the current processing solutions available,” said Matt Decker, Vice President of Technology, Payment Data Systems.

“Our new SDK helps to fulfill our continued commitment to attract developers in new industry verticals that are in need of secure payment processing solutions,” said Louis Hoch, President and Chief Operating Officer, Payment Data Systems.

PDS Checkout for Apple iOS provides easy integration with Payment Data Systems’s credit card and ACH processing platform. The software development kit (SDK) is compatible with all devices that run Apple’s iOS mobile operating system including Apple Watch, iPhone, iPad and Apple TV.  Learn more by visiting www.paymentdata.com/checkout.

About Payment Data Systems, Inc.
Payment Data Systems, Inc. (NASDAQ:PYDS), a leading integrated payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus and card issuers. The Company operates credit, debit/prepaid and ACH payment processing platforms to deliver convenient, world-class payment solutions and service to their clients. The strength of the Company lies in its ability to provide tailored solutions for card issuance, payment acceptance, and bill payments as well as its unique technology in the prepaid sector. Payment Data Systems, Inc. is headquartered in San Antonio, Texas, and has offices in New York, New York; and Los Angeles, California.

For additional information please visit www.paymentdata.com. Websites: www.ficentive.com, www.akimbocard.com, www.streamprepaid.com, www.zbill.com. Find us on Facebook®.

Apple, Apple Watch, iPhone, iPad, Apple TV and iOS are trademarks of Apple.

FORWARD-LOOKING STATEMENTS DISCLAIMER
Except for the historical information contained herein, the matters discussed in this release include certain forward-looking statements, which are intended to be covered by safe harbors. Those statements include, but may not be limited to, all statements regarding our and management’s intent, belief and expectations, such as statements concerning our future and our operating and growth strategy. Investors are cautioned that all forward-looking statements involve risks and uncertainties including, without limitation, the factors detailed from time to time in our filings with the Securities and Exchange Commission. One or more of these factors have affected, and in the future could affect our businesses and financial results in the future and could cause actual results to differ materially from plans and projections. We believe that the assumptions underlying the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available to our management. We assume no obligation to update any forward-looking statements, except as required by law.

Investor Contacts:
Julie MacMedan 
Elizabeth Brossy 
Financial Profiles
PYDS@finprofiles.com

$MTBC Launches Hospital Receivables Management Solution

$SPU Announces Formation of #SkyPeople International Trading (HK) Global #EMarketing Platform

The New Global E-Marketing Platform to Promote International Sales

XI’AN, China, July 28, 2016  — SkyPeople Fruit Juice, Inc. (NASDAQ: SPUN) (“SkyPeople” or “the Company”), a producer of fruit juice concentrates, fruit juice beverages and other fruit-related products, today announced that it has formed SkyPeople International Trading (HK) Limited (“SIT”), a subsidiary that has been incorporated in Hong Kong, to operate as a global trading and marketing platform to optimize SkyPeople’s Hedetang fruit juice product portfolio and reinforce its leading market position.

“We are very pleased about the creation of a new marketing platform for our fruit juice division and optimistic that it will result in meaningful penetration of the international marketplace,” said Mr. Yongke Xue, Chief Executive Officer of SkyPeople. “We are confident that our healthy beverage products will find a welcome reception in many countries as they are ideal for healthy and active lifestyles. We plan upon focusing on high quality organic fruit juice beverages for export and believe that our vertically integrated production capabilities will enable us to control costs even as we produce beverage products that are the very highest in quality.”

After completion of all of the required business registration procedures, SIT will be a wholly-owned subsidiary indirectly held by SkyPeople, mainly to provide online sales, marketing and post-sale services to more than 50 countries and regions worldwide including Malaysia, Thailand, Hong Kong and the United States.

SIT will operate as the online marketing and sales center for the Company, an international resources allocation center and a risk control center of e-commerce of international trade, and will engage in strategic planning and the development of e-commerce for the international market.

SIT will provide comprehensive online sales and services and is planned to be a high quality organic fruit juice beverage solution provider with an innovative business model and the objective of creating a market-oriented specialty international platform. According to the resolution of the Company’s Board of Directors on July 27^th, 2016, SIT will have an Executive Director and an international trade e-commerce center.

About SkyPeople Fruit Juice, Inc.

SkyPeople Fruit Juice, Inc., a Florida company, through its wholly-owned subsidiary Pacific Industry Holding Group Co., Ltd. (“Pacific”), a Vanuatu company, and SkyPeople Juice International Holding (HK) Ltd., a company organized under the laws of Hong Kong Special Administrative Region of the People’s Republic of China and a wholly owned subsidiary of Pacific, holds 73.42% ownership interest in SkyPeople Juice Group Co., Ltd. (“SkyPeople (China)”) and 100% ownership interest in SkyPeople Foods (China) Co., Ltd. (“SkyPeople Foods China”). SkyPeople (China) and (“SkyPeople Foods China”), together with their operating subsidiaries in China, are engaged in the production and sales of fruit juice concentrates, fruit beverages, and other fruit related products in the PRC and overseas markets. The Company’s fruit juice concentrates are sold to domestic customers and exported directly or via distributors. Fruit juice concentrates are used as a basic ingredient component in the food industry. Its brands, “Hedetang” and “SkyPeople,” which are registered trademarks in the PRC, are positioned as high quality, healthy and nutritious end-use juice beverages. For more information, please visit http://www.skypeoplefruitjuice.com.

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2014 and otherwise in our SEC reports and filings, including the final prospectus for our offering. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

For more information, please contact:

Hanjun Zheng, Interim Chief Financial Officer
SkyPeople Fruit Juice, Inc.
Tel: China  +86-29-8837-7161
Email: hanjun.zheng@skypeoplefruitjuice.com
Web: http://www.skypeoplefruitjuice.com

$CLBS Receives #FDA #FastTrack Designation for #CLBS03 in Type 1 #Diabetes

First Reported Fast Track Designation for a Type 1 Diabetes Treatment

BASKING RIDGE, N.J., July 28, 2016  — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider, PCT, with a select therapeutic development pipeline, announces today that its product candidate CLBS03 (autologous expanded polyclonal regulatory T cells, or Tregs) was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of type 1 diabetes mellitus (TID), making it the first known therapeutic candidate for treatment of T1D to receive the designation. CLBS03 has received Orphan Drug designation from the FDA as well as Advanced Therapeutic Medicinal Product (ATMP) classification from the European Medicines Agency. CLBS03 is currently being studied in a landmark Phase 2 clinical trial in collaboration with Sanford Health, The Sanford Project: T-Rex Study, which is expected to complete enrollment of the first defined cohort of 18 patients in the coming weeks.

Fast Track is a process designed to facilitate the development and expedite the review of drugs, biologics or treatments for serious conditions, thereby filling unmet medical needs. Through the Fast Track program, a product may be eligible for priority review at the time of a Biologic License Application (BLA) or New Drug Application (NDA) filing and may also be eligible to submit completed sections of the BLA/NDA on a rolling basis before the complete application is submitted. These expedited processes can significantly cut down the development time and cost associated with bringing a therapy to market. Furthermore, the therapy’s sponsors are eligible for more frequent written communication and meetings with the FDA, the benefit of which may be to foster a pivotal study design which more closely meets the FDA’s needs, thereby creating a more efficient and rapid pathway to approval.

The scientific basis for treating T1D with CLBS03 derives from the use of Tregs to treat autoimmune diseases caused by imbalances in an individual’s immune system. This innovative approach seeks to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, which are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune diseases, deficient Treg activity permits the T effector cells to attack the body’s own beneficial cells, for example, insulin-producing pancreatic beta cells in the case of T1D.

CLBS03 is a personalized, autologous medicine consisting of each patient’s own Tregs, which have been expanded in number and functionally enhanced by a proprietary method developed by a collaboration between PCT and the University of California, San Francisco.  The program is supported by promising published early clinical work conducted by respected leaders in the area of T regulatory cell science. Two Phase 1 clinical trials of this technology in T1D patients demonstrated safety and tolerance, feasibility of manufacturing, infused Treg persistence and an early indication of efficacy^1,2. In particular, one of those trials provided supportive evidence of the utility of Tregs for T1D in pediatric patients 8 to 16 years of age with new onset T1D². In that open label study, the authors reported that treatment with expanded autologous Tregs preserved function of pancreatic beta cells and reduced the need for exogenous insulin in the majority of patients treated.

“Obtaining Fast Track designation is a key milestone in our regulatory and development strategy for CLBS03.  It underscores the great need for innovative treatments, such as CLBS03, in the treatment of T1D and allows for the acceleration of its development,” said David J. Mazzo, PhD, Chief Executive Officer of Caladrius. “We are making excellent progress advancing the U.S.-based Phase 2 clinical program of CLBS03 to treat T1D and look to complete enrollment of the first cohort of 18 patients in the coming weeks. This, coupled with our Orphan Drug and Fast Track designations, should make CLBS03 an even more attractive opportunity for a potential partner.”

1. Bluestone, J., et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Translational Medicine, 2015 Nov;7(315): pp. 315ra189.
2. Marek-Trzonkowsa, N., et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets – results of one year follow-up. Clinical Immunology. 2014 Jul;153(1): 23-30.

About The Sanford Project: T-Rex Study 

The landmark study is a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of CLBS03 as a treatment for T1D with residual beta cell function in approximately 111 subjects age 12 to 17 in two cohorts (18 subjects followed by 93 subjects). The study is being conducted in collaboration with Sanford Research, a subsidiary of Sanford Health. Subjects will be randomized into one of three groups and will receive either a high dose of CLBS03, a low dose of CLBS03 or placebo.  The key endpoints for the trial are the standard medical and regulatory endpoints for a T1D trial and include preservation of C-peptide, an accepted measure for pancreatic beta cell function; insulin use; severe hypoglycemic episodes; and glucose and hemoglobin A1c levels.

About Caladrius Biosciences

Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry.  PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise.  Around the core expertise of PCT, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit www.caladrius.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties.  All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the realization of the benefits of fast track designation for CLB03, the achievement of clinical milestones for CLB03 including the completion of enrollment for the initial cohort of 18 patients and the establishment of a partnership for CLBS03. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC, including: risks related to:  (i) our expected continued losses and negative cash flows; (ii) our anticipated need for substantial additional financing; (iii) the significant costs and management resources required to comply with the requirements of being a public company;  (iv) the possibility that a significant market for cell therapy may not emerge; (v) the potential variability in PCT’s revenues; (vi) PCT’s limited manufacturing capacity; (vii) the need to improve manufacturing efficiency at PCT; (viii) the limited marketing staff and budget at PCT; (ix) the logistics associated with the distribution of materials produced by PCT; (x) government regulation; (xi) our intellectual property; (xii) cybersecurity; (xiii) the development, approval and commercialization of our products; (xiv) enrolling patients in and completing, clinical trials; (xv) the variability of autologous cell therapy; (xvi) our access to reagents we use in the clinical development of our cell therapy product candidates; (xvii) the validation and establishment of manufacturing controls; (xviii) the failure to obtain regulatory approvals outside the United States; (xix) our failure to realize benefits relating to “fast track” and “orphan drug” designations; (xx) the failure of our clinical trials to demonstrate the safety and efficacy of our product candidates; (xxi) our current lack of sufficient manufacturing capabilities to produce our product candidates at commercial scale; (xxii) our lack of revenue from product sales; (xxiii) the commercial potential and profitability of our products; (xxiv) our failure to realize benefits from collaborations, strategic alliances or licensing arrangements; (xxv) the novelty and expense of the technology used in our cell therapy business; (xxvi) the possibility that our competitors will develop and market more effective, safer or less expensive products than our product candidates; (xxvii) product liability claims and litigation, including exposure from the use of our products; (xxviii) our potential inability to retain or hire key employees; and (xxix) risks related to our capital stock. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

CONTACTS:

Investors:
LHA
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777
Email: afields@lhai.com

Media: 
Caladrius Biosciences, Inc.
Eric Powers
Director, Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com

$ISCO @intlstemcell #StemCell #Transplantation 1st Patient, Phase 1 #ISC #hpNSC #ClinicalTrial

ISC-hpNSC transplantation is being evaluated for the treatment of Parkinson’s Disease

CARLSBAD, Calif., July 28, 2016  — International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that the first patient in the previously announced Phase I clinical trial has undergone a successful intracranial transplant of ISC-hpNSC as a treatment under investigation for Parkinson’s Disease (PD). The operation took place at The Royal Melbourne Hospital in Australia.

The phase I clinical trial will evaluate the safety and tolerability of ISCO’s human parthenogenetic stem cell therapy, which uses cells that are cGMP and ethically manufactured through the company’s proprietary technology.

Andrey Semechkin, PhD, ISCO’s Co-Chairman and CEO, said, “We believe that stem cells are part of the solution to finding a cure for Parkinson’s Disease.  There is real potential for millions of people who currently suffer from Parkinson’s Disease to truly benefit from using ISC-hpNSC.”

Russell Kern, PhD, executive vice president and chief scientific officer of ISCO, commented, “This is a major step forward in our search for a cure for Parkinson’s Disease.  We are thrilled to initiate this clinical trial and prove that neural stem cells can be a part of the solution. We are hopeful that ISC-hpNSC will prove to be a valuable therapy. The operation which took place at The Royal Melbourne Hospital to transplant neural stem cells into the patient’s brain went according to plan.”

About the clinical study

The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC^®, intracranially transplanted into patients with moderate to severe Parkinson’s disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson’s disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC^®. PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC^® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales.

The study is underway at The Royal Melbourne Hospital in Australia. The study is being overseen by ISCO subsidiary, Cyto Therapeutics Pty Ltd.

About Parkinson’s disease

Parkinson’s disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson’s disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson’s disease is more common in older people, with most cases occurring after the age of 50.

Currently, medications typically used in the treatment of Parkinson’s, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.

About ISC-hpNSC ^®

International Stem Cell Corporation’s proprietary ISC-hpNSC^® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC^® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson’s disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC^®. ISC-hpNSC^® provides neurotrophic support and cell replacement to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSC^® are safe, well tolerated and do not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC^® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, expected results and timing of clinical studies, potential applications of ISC-hpNSC^® to other diseases, progress of research and development initiatives, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email: ir@intlstemcell.com

Alex Fudukidis
Russo Partners
Tel.: +1 646 942 5632
E-mail: alex.fudukidis@russopartnersllc.com

$DRAM Regains #Compliance with #NASDAQ Minimum Bid Price Rule

PRINCETON, N.J., July 27, 2016  — Dataram Corporation (NASDAQ: DRAM), an independent manufacturer of memory products and provider of performance solutions, today reported that it has received formal notification from the Listing Qualifications Department of The NASDAQ Stock Market (“NASDAQ”) notifying Dataram that it has regained compliance with Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on The NASDAQ Stock Market, and that the matter is now closed.  Dataram’s common stock will continue to be listed on The NASDAQ Capital Market.

On January 27, 2016, NASDAQ notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by NASDAQ’s Listing Rules. On July 11, 2016, Dataram effected a one for three (1 for 3) reverse split of its outstanding common stock in order to increase its stock price to above the required $1 per share, which was effective with NASDAQ at the open of trading on July 11, 2016.  Since then, NASDAQ has determined that for the 10 consecutive business days from July 11, 2016 to July 25, 2016, the closing bid price of the Company’s common stock has been at $1.00 per share or greater.  On July 26, 2016, NASDAQ provided confirmation to Dataram of the foregoing and that the Company has regained compliance with Listing Rule 5550(a)(2).

Dataram’s common stock trades on The NASDAQ Capital Market under the symbol “DRAM.”

“We are very pleased to have regained compliance with NASDAQ’s listing rules,” said Dave Moylan, Chairman and Chief Executive Officer (CEO) of the Company.  “Maintaining our NASDAQ listing is vital to our Company, our shareholders and customers as we continue to execute our plan to transform Dataram.  We believe our shareholders will benefit from the enhanced liquidity provided by the listing of the Company’s shares on The NASDAQ Capital Market.”

About Dataram Corporation
Dataram is an independent manufacturer of memory products and provider of performance solutions that increase the performance and extend the useful life of servers, workstations, desktops and laptops sold by leading manufacturers such as Dell, Cisco, Fujitsu, HP, IBM, Lenovo and Oracle. Dataram’s memory products and solutions are sold worldwide to OEMs, distributors, value-added resellers and end users. Additionally, Dataram manufactures and markets a line of Intel Approved memory products for sale to manufacturers and assemblers of embedded and original equipment. 70 Fortune 100 companies are powered by Dataram. Founded in 1967, the Company is a US based manufacturer, with presence in the United States, Europe and Asia. For more information about Dataram, visit www.dataram.com.

Safe Harbor
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These risks include, but are not limited to, risks and uncertainties associated with the price of the Company’s common stock and its ability to satisfy the continued listing standards of The NASDAQ Stock Market, the impact of economic, competitive and other factors affecting the Company and its operations, markets, products, changes in the price of memory chips, changes in the demand for memory systems, increased competition in the memory systems industry, order cancellations, delays in developing and commercializing new products, risks related  to the Company’s previously announced acquisition target, U.S. Gold Corp., faced by junior exploration companies generally engaged in pre-production activities; maintenance of important business relationships; and other factors described in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including  the Risk Factors with respect to U.S. Gold contained in the Current Report on Form 8-K filed on June 13, 2016, filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov.  The Company has based these forward-looking statements on its current expectations and assumptions about future events.  While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control.  The Company does not assume any obligations to update any of these forward-looking statements.

For additional information, please contact:
Robert Haag
Managing Director
IRTH Communications
866-976-4784
DRAM@irthcommunications.com

Dataram Contact:
Jeffrey Goldenbaum
Director, Marketing
609-799-0071
info@dataram.com

$PYDS Expands #ACH #Network with New #ODFI #Banking Relationship

SAN ANTONIO, July 27, 2016  — Payment Data Systems, Inc. (NASDAQ:PYDS) today announced that it has established a fourth Originating Depository Financial Institution (ODFI) relationship, expanding its ACH processing network for merchant customers.

“We brought on this new ACH banking partner to better serve the needs of important customers.  It expands our competitive advantage in the ACH processing arena and provides additional capacity, stability and readiness to existing and future customers by offering them an additional channel to transmit payment traffic to the Federal Reserve network.  Operationally, it adds redundancy and better risk management to our system ensuring that we can provide the highest level of service in the industry,” said Louis Hoch, President and COO, Payment Data Systems, Inc.  “The additional ACH network capacity is expected to increase traffic from existing merchants who have already expressed interest in maintaining multiple banking relationships, as well as help us to attract new clients to our platform.”

“In financial technology, strategic bank partnerships are critical. These partners help us define the parameters around the products and services we can build and offer. Peer-to-peer services like PayPal, processing companies like Square and Stripe, and even blockchain exchanges like Coinbase were all created from bank partnerships with financial technology companies.  Our ability to build these partnerships in an era of ever-increasing regulation on banks has become a key component to reinforcing our competitive advantage and building barriers to the competition,” added Mr. Hoch.

About Payment Data Systems, Inc.
Payment Data Systems, Inc. (NASDAQ:PYDS), a leading integrated payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus and card issuers. The Company operates credit, debit/prepaid and ACH payment processing platforms to deliver convenient, world-class payment solutions and service to their clients. The strength of the Company lies in its ability to provide tailored solutions for card issuance, payment acceptance, and bill payments as well as its unique technology in the prepaid sector. Payment Data Systems, Inc. is headquartered in San Antonio, Texas, and has offices in New York, New York; and Los Angeles, California.

For additional information please visit www.paymentdata.com. Websites: www.ficentive.com, www.akimbocard.com, www.streamprepaid.com, www.zbill.com. Find us on Facebook®.

FORWARD-LOOKING STATEMENTS DISCLAIMER
Except for the historical information contained herein, the matters discussed in this release include certain forward-looking statements, which are intended to be covered by safe harbors. Those statements include, but may not be limited to, all statements regarding our and management’s intent, belief and expectations, such as statements concerning our future and our operating and growth strategy. Investors are cautioned that all forward-looking statements involve risks and uncertainties including, without limitation, the factors detailed from time to time in our filings with the Securities and Exchange Commission. One or more of these factors have affected, and in the future could affect our businesses and financial results in the future and could cause actual results to differ materially from plans and projections. We believe that the assumptions underlying the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available to our management. We assume no obligation to update any forward-looking statements, except as required by law.

Investor Contacts:
Julie MacMedan 
Elizabeth Brossy 
Financial Profiles
PYDS@finprofiles.com

$STB C$85M Convertible Unsecured Subordinated Debenture Bought Deal Offering

Proceeds to be used to redeem higher rate debentures maturing June 30, 2018

Student Transportation Inc.
Doug Coupe
Director of Communications & Investor Relations
(843) 884-2720
dcoupe@ridesSTA.com

$MDGS Receives First #MUSE #PurchaseOrder From #JohnsHopkins

World renowned healthcare institution purchases its first MUSE console and device to offer GERD patients a minimally-invasive treatment option

OMER, Israel, July 27, 2016  — Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that Johns Hopkins Hospital, an integrated global health enterprise and one of the leading health care systems in the United States, has provided an initial purchase order (PO) for the MUSE™ system. The PO covers the cost of a MUSE system console and endoscopic device, which will be available for use on eligible patients suffering from GERD.

The Medigus Ultrasonic Surgical Endostapler, or MUSE system, is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device is equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication — the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).

“We thank Johns Hopkins for its recognition of our technology as a minimally-invasive modality that addresses the widening gap in GERD treatment between drug therapy and invasive surgery,” said Chris Rowland, CEO of Medigus. “GERD is a pervasive disorder that has the potential to worsen into more severe conditions if not properly addressed at the early stages. We are proud to have this interventional endoscopic treatment be available to Baltimore area patients.”

According to experts, 60 percent of the American adult population will experience some type of GERD within year and 20 to 30 percent will have weekly symptoms.¹ GERD, the medical term for acid reflux, occurs when the base of the lower esophageal sphincter doesn’t properly close after swallowing, which allows acids to back up (or reflux) into the esophagus, causing discomfort. Though patients may experience symptom relief through acid-reducing medications called Proton Pump Inhibitors (PPIs), these do not treat the anatomical source of GERD, leaving opportunity for the disease to progress to a more severe condition, including esophageal cancer.

To learn how MUSE works or to find a physician near you who offers this treatment, please visit www.refluxhelp.com.

About GERD
Gastroesophageal reflux disease (GERD) occurs when the lower esophageal sphincter spontaneously opens or does not properly close after use, allowing stomach acids to rise (or reflux) into the esophagus, which causes heartburn, irritation and potentially other discomforts. GERD affects approximately 81 million Americans each year, 8.6 million of whom experience severe symptoms.ⁱ While some patients can attain symptom relief through the use of proton pump inhibitors, or PPIs, (acid reducing medications), there is growing concern around the prolonged use of PPIs, including increased risk of renal failureⁱⁱ, dementiaⁱⁱⁱ, bone fracture and interference with the adsorption of essential vitamins and minerals.^iv A persistent state of untreated GERD may lead to Barrett’s esophagus, a precancerous condition which can progress to esophageal cancer. Patients who suffer from persistent GERD are seven times more likely to develop esophageal cancer.ⁱⁱ

About The MUSE™ System
The MUSE™ system is a flexible transoral stapler that enables a minimally-invasive procedure for the long-term treatment of GERD. The device is fully integrated with latest technological advancements in microvisualization, ultrasound and surgical stapling, which allows a single physician or surgeon to perform anterior partial fundoplication more easily than with leading laparoscopic methods. Its intuitive endosurgical platform consists of a single use flexible surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder, and includes a handle with controls, an 80 cm flexible shaft, a 5 cm rigid section holding a cartridge with 5 standard 4.8mm titanium surgical staples, a ratchet controlled one-way articulating section, and a new, rounded distal tip for easier insertion. The MUSE system is FDA cleared and CE marked for the treatment of GERD and is reimbursable in the U.S. under Current Procedural Terminology (CPT^®) code 43210 for Esophagogastric Fundoplasty Trans-Orifice Approach. CPT codes are descriptive terms physicians use for reporting all medical, surgical, and diagnostic services and procedures; Category I codes are most frequently used by healthcare providers when reporting a significant portion of their services. MUSE also has obtained the necessary licenses to market the product in Canada and Israel. For more information, visit www.RefluxHelp.com.

This press release may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions and expectations of the company’s management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.  These forward-looking statements represent Medigus’ expectations or beliefs concerning future events, and it is possible that the results described in this news release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the company’s activity to differ significantly from the content and implications of such statements. Among the factors which may cause the actual results to differ from the Forward-Looking Statements are changes in the target market and the introduction of competitive products, our ability to secure favorable reimbursement rates, regulatory, legislative and policy changes, and clinical results. Other risk factors affecting the company are discussed in detail in the Company’s filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.

MEDIA CONTACT:
Chantal Beaudry/ Carrie Yamond
Lazar Partners Ltd.
212-867-1762
cbeaudry@lazarpartners.com
cyamond@lazarpartners.com

INVESTOR RELATIONS (U.S.):
David Carey
Lazar Partners Ltd.
212-867-1768
dcarey@lazarpartners.com

INVESTOR RELATIONS (Israel):
Iris Lubitch/ Noam Yellin
SmarTeam
972-3-6954333
Iris@Smartteam.co.il
Noam@Smartteam.co.il

¹ http://www.healthline.com/health/gerd/statistics#1

ⁱ Rubenstein JH & Taylor JB. (2010). Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Alimentary Pharmacology & Therapeutics, 32(10):1222-7. doi: 10.1111/j.1365-2036.2010.04471.x. Epub 2010 Sep 23.

ⁱⁱ Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E. (2016). Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine JAMA Intern Med, 176(2). doi:10.1001/jamainternmed.2015.7193

ⁱⁱⁱ Gomm, W., Holt, K. V., Thomé, F., Broich, K., Maier, W., Fink, A., . . . Haenisch, B. (2016). Association of Proton Pump Inhibitors With Risk of Dementia. JAMA Neurology JAMA Neurol, 73(4), 410. doi:10.1001/jamaneurol.2015.4791

^iv Tetsuhide Ito, MD, PhD & Robert T. Jensen, MD (2010). Association of Long-term Proton Pump Inhibitor Therapy with Bone Fractures and effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium. Current Gastroenterology Reports, 12(6): 448–457. doi:  10.1007/s11894-010-0141-0

$SAEX Announces Closing of #ExchangeOffer and #ConsentSolicitation

HOUSTON, July 27, 2016 — SAExploration Holdings, Inc. (NASDAQ:SAEX), or SAE, today announced that it has completed its previously announced exchange offer and consent solicitation related to its outstanding 10.000% Senior Secured Notes due 2019 (the “Existing Notes”). SAE offered to exchange (the “Exchange Offer”) any and all of the Existing Notes held by eligible holders upon the terms and subject to the conditions set forth in SAE’s Exchange Offer Memorandum and Consent Solicitation Statement dated June 24, 2016 (together with the related letter of transmittal, the “Memorandum”).

Brian Beatty, President and CEO of SAE, said, “We are very pleased with the success of our exchange offer in which almost 99% of our outstanding Existing Notes were exchanged. As part of our comprehensive restructuring, this provides SAE with enhanced liquidity, meaningful financial flexibility and a realigned balance sheet, which will make us even more competitive in the current environment and position us for long-term growth and continued success.”

The Exchange Offer and Consent Solicitation expired at 11:59 p.m., New York City time, on July 22, 2016. In exchange for $138,128,000 in aggregate principal amount of the Existing Notes, representing approximately 98.7% of the outstanding aggregate principal amount of the Existing Notes, validly tendered (and not validly withdrawn) in the Exchange Offer, SAE issued (i) $69,064,000 aggregate principal amount of new 10.000% Senior Secured Second Lien Notes due 2019 (the “New Notes”) and (ii) 6,410,502 new shares of SAE’s common stock (the “Shares”), after giving effect to a 135-to-1 reverse stock split. SAE delivered cash in lieu of any fractional shares. In addition, each participating holder received accrued and unpaid interest on its tendered Existing Notes that were accepted for exchange from their last interest payment date to, but not including, the settlement date, which was paid in the form of additional New Notes, in an aggregate amount of $7,458,912. The New Notes will bear interest at a rate of 10.000% per annum payable in cash, accruing from the settlement date, provided that for each interest payment through and including July 15, 2017, SAE may, at its option, pay interest in kind by issuing additional New Notes (“PIK Notes”). Interest paid in kind will accrue at a rate per annum of 11.0%, and any PIK Notes will be fungible with, and will accrue interest at the same rate as, the New Notes. The New Notes will be fully and unconditionally guaranteed on a senior secured second lien basis by each of SAE’s existing and future domestic restricted subsidiaries, except for immaterial subsidiaries and foreign subsidiaries (the “New Guarantees”). These are the same subsidiaries that currently guarantee the Existing Notes.

The New Notes and the New Guarantees will be secured by a second-priority lien on substantially all of SAE’s and the guarantors’ assets, subject to certain exceptions and permitted liens. The liens on assets that secure the New Notes and the New Guarantees will be contractually subordinated to liens securing SAE’s existing revolving credit facility with Wells Fargo Bank (the “Existing Revolving Credit Facility”) and the previously announced $30 million multi-draw senior secured term loan facility that SAE entered into on June 29, 2016 with certain holders of Existing Notes (the “New Senior Loan Facility”), as described in the Memorandum. The liens on assets that secure the New Notes and the New Guarantees will be senior to those securing any Existing Notes (and the guarantees thereof) that remain outstanding following the Exchange Offer. The New Notes and the New Guarantees will be subordinated to indebtedness under the Existing Revolving Credit Facility and New Senior Loan Facility to the extent of the value of such collateral. The New Notes and the New Guarantees will not be secured by the assets of SAE’s subsidiaries that do not guarantee the New Notes.

The complete terms and conditions of the Exchange Offer and Consent Solicitation are set forth in the Memorandum. The Exchange Offer and Consent Solicitation are part of a comprehensive restructuring by SAE, additional elements of which are described in SAE’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 13, 2016.

In connection with the comprehensive restructuring, SAE also announced today that it has issued two series of warrants (“Series A Warrants” and “Series B Warrants”, together the “Warrants”) to the existing holders of their common stock as of July 26, 2016 (the “Existing Holders”). The Series A Warrants and the Series B Warrants were both allocated to the Existing Holders at a rate of 1.180714 Warrants per share of common stock held by the Existing Holders on July 27, 2016 on an aggregate basis. The complete terms and conditions of the Warrants are set forth in the warrant agreement to be attached as an exhibit to the Company’s Current Report on Form 8-K to be filed with the SEC in connection with the closing of the Exchange Offer and Consent Solicitation.

The New Notes, the New Guarantees, Shares and Warrants issued have not been registered under the Securities Act of 1933 or any state securities laws, and unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of any of these securities, in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

D.F. King & Co., Inc. acted as Information Agent and Exchange Agent.

Forward Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws with respect to SAE. These statements can be identified by the use of words or phrases such as “expects,” “estimates,” “projects,” “budgets,” “forecasts,” “anticipates,” “intends,” “plans,” “may,” “will,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions. These forward-looking statements include statements regarding SAE’s financial condition, results of operations and business and SAE’s expectations or beliefs concerning future periods and possible future events, including regarding SAE’s ability to succeed in, or realize the benefits of, any of the restructuring and recapitalization transactions. These statements are subject to significant known and unknown risks and uncertainties that could cause actual results to differ materially from those stated in, and implied by, this press release. Risks and uncertainties that could cause actual results to vary materially from SAE’s expectations are described under “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in SAE’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as amended by Amendment No. 1 thereto. Except as required by applicable law, SAE is not under any obligation to, and expressly disclaims any obligation to, update or alter its forward looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

Contact

SAExploration Holdings, Inc.
Ryan Abney
Vice President, Capital Markets & Investor Relations
(281) 258-4409
rabney@saexploration.com

$TXN Debuts #WPC v1.2 #Qi #Certified 15W #Wireless #PowerTransmitter

Industry’s most efficient 15-W solution delivers high power and fast-charge wireless charging to industrial applications

DALLAS, July 26, 2016  — Texas Instruments (TI) (NASDAQ: TXN) today introduced the industry’s first Wireless Power Consortium (WPC) v1.2 Qi-certified 15-W wireless power transmitter. The bq501210 enables 84 percent system efficiency with significantly less thermal dissipation than traditional wireless power devices. The transmitter supports multiple fast-charging protocols and offers an array of flexible and customizable features such as personal electronics, medical and space-constrained industrial applications. To learn more about the bq501210, visit www.ti.com/bq501210-pr.

Industrial end equipment such as electronic point-of-sale devices and handheld medical equipment reap the benefits of 15-W wireless power. This breakthrough in technology enables connectorless models and reduces overall end-application size by helping eliminate the need for bulky wiring.

Features and benefits of the bq501210

• System efficiency at 84 percent: Fixed-frequency operation helps achieve the industry’s highest 15-W efficiency as well as reducing electromagnetic interference (EMI).
• Fast-charging capability: Fast-charge negotiation with mobile devices enables the transfer of up to 10 W to compatible receivers, including existing fast-charging devices on the market.
• Wide-voltage aptitude: The High-Voltage Dedicated Charging Port (HVDCP) protocol negotiates with capable AC/DC wall adapters to adjust the input voltage. The rail control output provides power to deliver a full 15 W with inputs between 15 V and 19 V, and enables lower power operation, such as 5 W, with inputs as low as 5 V.

The new 15-W transmitter joins TI’s proven portfolio of scalable wireless power solutions, which also includes 2.5-W, 5-W and 10-W products that provide designers with best-in-class thermal ratings and wide input-voltage and output power ranges, along with customizable sizes and power levels to fit a wide variety of wireless power needs.

Tools and support
Engineers can speed time to market and easily evaluate the new device’s features and performance with the bq501210 evaluation module (EVM). The bq501210EVM-756 is available for US$149.

Availability and pricing
The bq501210 transmitter is shipping in volume production now and is available through the TI store and the company’s authorized distribution network. The bq501210 comes in a 9-mm-by-9-mm very thin quad flat no-lead (VQFN) package and is priced at US$3.75 in 1,000-unit quantities.

Find out more about TI’s wireless power solutions

• Read the blog post, “What does wireless power mean for industrial applications?”
• Check out TI’s battery-management solutions.
• Visit the TI E2E™ Community Battery Management forum to search for solutions, get help, share knowledge, and solve problems with fellow engineers and TI experts.

TI and wireless power
TI’s wireless power-management products enable innovative, efficient wireless charging capabilities for mobile phones, tablets and other portable electronics, and wireless power charging transmitters ranging from stand-alone charging pads to those embedded in cars and furniture. The company offers the most extensive portfolio of power integrated circuits (ICs) that support the WPC’s Qi standard and the AirFuel Alliance standard.

About Texas Instruments
Texas Instruments Incorporated (TI) is a global semiconductor design and manufacturing company that develops analog ICs and embedded processors. By employing the world’s brightest minds, TI creates innovations that shape the future of technology. TI is helping more than 100,000 customers transform the future, today. Learn more at www.ti.com.

Trademarks
TI E2E is a registered trademark of Texas Instruments. All other trademarks belong to their respective owners.

$HSII Declares #Quarterly #Cash #Dividend

CHICAGO, July 26, 2016  — Heidrick & Struggles International, Inc. (NASDAQ: HSII), a premier provider of senior-level executive search, leadership consulting and culture shaping services globally, today announced that its Board of Directors has declared a quarterly cash dividend of $0.13 per share.  The dividend is payable on August 19, 2016 to shareholders of record at the close of business on August 5, 2016.

About Heidrick & Struggles International, Inc.
Heidrick & Struggles (Nasdaq: HSII) serves the executive talent and leadership needs of the world’s top organizations as a premier provider of leadership consulting, culture shaping and senior-level executive search services. Heidrick & Struggles pioneered the profession of executive search more than 60 years ago. Today, the firm serves as a trusted advisor, providing integrated leadership solutions and helping its clients change the world, one leadership team at a time. www.heidrick.com.

Press Release Contact:

H&S Investors & Analysts Contact:
Julie Creed – Vice President, Investor Relations & Real Estate
+1 312.496.1774, jcreed@heidrick.com

$LLTC #LinearTechnology to be #Acquired by $ADI #AnalogDevices

Analog Devices, Inc. (NASDAQ: ADI) (“Analog Devices”) and Linear Technology Corporation (NASDAQ: LLTC) (“Linear Technology”) today announced that they have entered into a definitive agreement under which Analog Devices will acquire Linear Technology in a cash and stock transaction that values the combined enterprise at approximately $30 billion⁽¹⁾. Upon completion of the acquisition, Analog Devices will be the premier global analog technology company with approximately $5 billion in anticipated annual revenues.

Under the terms of the agreement, Linear Technology shareholders will receive $46.00 per share in cash and 0.2321 of a share of Analog Devices common stock for each share of Linear Technology common stock they hold at the closing of the transaction. The transaction values Linear Technology at approximately $60.00 per share⁽¹⁾, representing an equity value for Linear Technology of approximately $14.8 billion⁽¹⁾.

“The combination of Analog Devices and Linear Technology brings together two of the strongest business and technology franchises in the semiconductor industry,” said Vincent Roche, President and Chief Executive Officer of Analog Devices. “Our shared focus on engineering excellence and our highly complementary portfolios of industry-leading products will enable us to solve our customers’ biggest and most complex challenges at the intersection of the physical and digital worlds. We are creating an unparalleled innovation and support partner for our industrial, automotive, and communications infrastructure customers, and I am very excited about what this acquisition means for our customers, our employees, and our industry.”

Bob Swanson, Executive Chairman and Co-founder of Linear Technology, added, “For 35 years, Linear Technology has had great success by growing its business organically. However, this combination of Linear Technology and Analog Devices has the potential to create a combination where one plus one truly exceeds two. As a result, the Linear Technology Board concluded that this is a compelling transaction that delivers substantial value to our shareholders, and the opportunity for additional upside through stock in the combined company. Analog Devices is a highly respected company. By combining our complementary areas of technology strength, we have an excellent opportunity to reinforce our leadership across the analog and power semiconductor markets, enhancing shareholder value. Together, Linear Technology and Analog Devices will advance the technology and deliver innovative analog solutions to our customers worldwide. We are committed to working with the ADI team to ensure a smooth transition.”

Compelling Strategic and Financial Benefits

• Global High-Performance Analog Industry Leader: Combination expected to create a global high-performance analog industry leader across data converters, power management, amplifiers, interface, and RF and microwave products
• Highly Complementary Businesses: Highly complementary product portfolios create the industry’s most comprehensive suite of high-performance analog offerings and expand Analog Devices’ total addressable market to $14 billion from $8 billion
• Leading Positions & Commitment to Customers: Combined company expected to be a leader across all major high-performance analog product categories and will have a shared commitment to providing customers with the highest levels of innovation, service, and support
• Accelerates Innovation and Revenue Growth in Attractive Markets: Unique combination of engineering excellence and domain expertise accelerates innovation and revenue growth opportunities in the industrial, automotive, and communications infrastructure markets
• Best-in-Class Financial Model: Value of innovation and engineering excellence reflected in best-in-class financial model, non-GAAP margins, and free cash flow
• Accretive Transaction: The transaction is expected to be immediately accretive to Analog Devices’ non-GAAP EPS and free cash flow. Analog Devices expects to achieve $150 million of annualized run-rate cost synergies within 18 months post transaction close

Mr. Roche concluded, “We have tremendous respect and admiration for the franchise created by Linear Technology. I have no doubt that the combination of our two companies will create a trusted leader in our industry, capable of generating tremendous value for all of our stakeholders.”

Following the transaction close, Mr. Roche, President and CEO of Analog Devices will continue to serve as President and CEO of the combined company, and David Zinsner, SVP and CFO of Analog Devices, will continue to serve as SVP and CFO of the combined company. Analog Devices and Linear Technology anticipate a combined company leadership team with strong representation from both companies across all functions. The Linear Technology brand will continue to serve as the brand for Analog Devices’ power management offerings. The combined company will use the name Analog Devices, Inc. and continue to trade on the NASDAQ under the symbol ADI.

Transaction Structure and Terms
Under the terms of the agreement, Linear Technology shareholders will receive $46.00 per share in cash and 0.2321 of a share of Analog Devices common stock for each share of Linear Technology common stock they hold at closing. The transaction values Linear Technology at approximately $60.00 per share⁽¹⁾, representing an equity value for Linear Technology of approximately $14.8 billion⁽¹⁾. Post-closing, Linear Technology shareholders will own approximately 16% of the combined company on a fully-diluted basis.

Analog Devices intends to fund the transaction with approximately 58 million new shares of Analog Devices common stock, approximately $7.3 billion of new long-term debt, and the remainder from the combined company’s balance sheet cash. The new long-term debt is supported by a fully underwritten bridge loan commitment and is expected to consist of term loans and bonds, with emphasis on pre-payable debt, to facilitate rapid deleveraging.

This transaction has been unanimously approved by the boards of directors of both companies. Closing of the transaction is expected by the end of the first half of calendar year 2017, and is subject to regulatory approvals in various jurisdictions, the approval of Linear Technology’s shareholders, and other customary closing conditions.

Analog Devices Financial Guidance
Analog Devices also narrowed and raised its financial guidance for its third quarter of fiscal year 2016, for revenue to be approximately $865 million, and for diluted earnings per share to be in the range of $0.71 to $0.72, and non-GAAP diluted earnings per share to be in the range of $0.77 to $0.78. The non-GAAP EPS estimate reflects estimated adjustments for amortization of purchased intangible assets and depreciation of step up value on purchased fixed assets, which total $19 million in the aggregate.

Advisors
Credit Suisse is acting as exclusive financial advisor to Analog Devices, and Wachtell, Lipton, Rosen & Katz and Wilmer Cutler Pickering Hale and Dorr LLP are serving as its legal advisors. J.P. Morgan, Bank of America Merrill Lynch, and Credit Suisse are providing committed debt financing for the transaction. Qatalyst Partners is acting as exclusive financial advisor to Linear Technology, and Jones Day is serving as its legal advisor.

Conference call and Webcast Information
Analog Devices and Linear Technology management will host a conference call today, July 26, 2016 at 5:00pm ET to discuss details of the transaction. A live webcast and the accompanying presentation relating to the transaction will be available in the “investors” section of Analog Devices’ website at www.analog.com in advance of the conference call.

Investors may join via webcast, accessible at investor.analog.com, or by telephone (call 800-859-9560 ten minutes before the call begins and provide the password “ADI”).

A replay of the call will be made available and may be accessed for up to two weeks by dialing (855) 859-2056 (replay only) and providing the conference ID: 56173988, or by visiting investor.analog.com.

About Analog Devices
Analog Devices designs and manufactures semiconductor products and solutions. We enable our customers to interpret the world around us by intelligently bridging the physical and digital with unmatched technologies that sense, measure and connect. Visit http://www.analog.com.

About Linear Technology
Linear Technology, a member of the S&P 500, has been designing, manufacturing and marketing a broad line of high performance analog integrated circuits for major companies worldwide for over three decades. The company’s products provide an essential bridge between our analog world and the digital electronics in communications, networking, industrial, automotive, computer, medical, instrumentation, consumer, and military and aerospace systems. Linear Technology produces power management, data conversion, signal conditioning, RF and interface ICs, µModule® subsystems, and wireless sensor network products. For more information, visit www.linear.com.

Note:
(1) Based on Analog Devices’ 5-day volume weighted average price of $60.3215 as of July 21, 2016 per Bloomberg.

Forward Looking Statements

This press release contains forward-looking statements, which address a variety of subjects including, for example, the expected timetable for closing of the transaction between Analog Devices, Inc. (“Analog Devices”) and Linear Technology Corporation (“Linear Technology”), the expected benefits and synergies of the transaction, including the effect of the transaction on Analog Devices’ revenues, non-GAAP earnings, free cash flow, capital returns and expected growth rates of the combined companies, Analog Devices’ expected product offerings, product development, marketing position and technical advances resulting from the transaction, the availability of debt financing for the transaction, Analog Devices’ timing and ability to repay the debt and Analog Devices’ guidance for its third quarter of fiscal 2016. Statements that are not historical facts, including statements about our beliefs, plans and expectations, are forward-looking statements. Such statements are based on our current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability to satisfy the conditions to closing of the proposed transaction, on the expected timing or at all; the ability to obtain required regulatory approvals for the proposed transaction, on the expected timing or at all, including the potential for regulatory authorities to require divestitures in connection with the proposed transaction; the occurrence of any event that could give rise to the termination of the merger agreement; the risk of stockholder litigation relating to the proposed transaction, including resulting expense or delay; higher than expected or unexpected costs associated with or relating to the transaction; the risk that expected benefits, synergies and growth prospects of the transaction may not be achieved in a timely manner, or at all; the risk that Linear Technology’s business may not be successfully integrated with Analog Devices’ following the closing; the risk that Analog Devices and Linear Technology will be unable to retain and hire key personnel; and the risk that disruption from the transaction may adversely affect Linear Technology’s or Analog Devices’ business and relationships with their customers, suppliers or employees. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to both Analog Devices’ and Linear Technology’s filings with the Securities and Exchange Commission (“SEC”), including the risk factors contained in each of Analog Devices’ and Linear Technology’s most recent Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Important Additional Information Will Be Filed With The SEC

In connection with the proposed transaction, Analog Devices and Linear Technology intend to file relevant information with the SEC, including a registration statement of Analog Devices on Form S-4 (the “registration statement”) that will include a prospectus of Analog Devices and a proxy statement of Linear Technology (the “proxy statement/prospectus”). INVESTORS AND SECURITY HOLDERS OF LINEAR TECHNOLOGY ARE URGED TO CAREFULLY READ THE ENTIRE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANALOG DEVICES, LINEAR TECHNOLOGY AND THE PROPOSED TRANSACTION. A definitive proxy statement/prospectus will be sent to Linear Technology’s shareholders. The registration statement, proxy statement/prospectus and other documents filed by Analog Devices with the SEC may be obtained free of charge at Analog Devices’ website at www.analog.com or at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge from Analog Devices by requesting them by mail at Analog Devices, Inc., One Technology Way, P.O. Box 9106, Norwood, MA 02062-9106, Attention: Investor Relations, or by telephone at (781) 461-3282. The documents filed by Linear Technology with the SEC may be obtained free of charge at Linear Technology’s website at www.linear.com or at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge from Linear Technology by requesting them by mail at Linear Technology Corporation, 1630 McCarthy Blvd., Milpitas, CA, 95035-7417, Attention: Investor Relations, or by telephone at (408) 432-2407.

Participants in the Solicitation

Linear Technology, Analog Devices and certain of their directors, executive officers and employees may be deemed participants in the solicitation of proxies from Linear Technology shareholders in connection with the proposed transaction. Information regarding the persons who may be deemed to be participants in the solicitation of Linear Technology shareholders in connection with the proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus when it is filed with the SEC. Information about the directors and executive officers of Analog Devices and their ownership of Analog Devices’ common stock is set forth in the definitive proxy statement for the Analog Devices’ 2016 annual meeting of shareholders, as previously filed with the SEC on January 28, 2016. Information about the directors and executive officers of Linear Technology and their ownership of Linear Technology common stock is set forth in the definitive proxy statement for Linear Technology’s 2015 annual meeting of shareholders, as previously filed with the SEC on September 17, 2015. Free copies of these documents may be obtained as described in the paragraphs above.

Non-Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160726006455/en/

Investor Contacts
Analog Devices:
Ali Husain, 781-461-3282
Treasurer & Director of Investor Relations
investor.relations@analog.com
or
Mike Lucarelli, 781-461-3282
Senior Manager Investor Relations
investor.relations@analog.com
or
Linear Technology:
Donald P. Zerio, 408-432-1900
Vice President, Finance, Chief Financial Officer
or
Media Contacts
Analog Devices:
Gerald Kimber White, 781-461-3839
Senior Director Corporate Communications
gerald.kimberwhite@analog.com
or
Sard Verbinnen & Co:
John Christiansen, 415-618-8750
jchristiansen@sardverb.com
or
Margaret Popper, 212-687-8080
mpopper@sardverb.com
or
Linear Technology:
John Hamburger, 408-432-1900 x2419
Director, Marketing Communications
jhamburger@linear.com

$LOGM #LogMeIn #Merger w/ $CTXS #Citrix #GoTo Family of Products

Combined Entity will be a Leading SaaS Company with a Diverse and Innovative Product Portfolio

Expected First Year Post Close Pro Forma Revenue of $1+ Billion, Anticipated Adjusted EBITDA Margins of 35% in 2017, Anticipated Pro Forma 35%+ Free Cash Flow Accretion over Standalone LogMeIn after Realizing Run Rate Synergies

Run Rate Cost Synergies of $65 Million Expected in Year One and More than $100 Million Expected in Year Two

Bill Wagner, LogMeIn President and CEO, to Lead Combined Company

Citrix and LogMeIn Shareholders to Each Own Approximately 50% of Combined Company

LogMeIn Plans to Issue $1.50 per Share in Dividends to its Shareholders Prior to the Closing

BOSTON and SANTA CLARA, Calif., July 26, 2016  — LogMeIn, Inc. (NASDAQ:LOGM) and Citrix Systems, Inc. (NASDAQ:CTXS) today announced that the companies have entered into a definitive merger agreement for LogMeIn to combine with Citrix’s GoTo business in a Reverse Morris Trust transaction.  The transaction is valued at approximately $1.8 billion based on shares to be issued and LogMeIn’s closing price of $65.31 as of July 25, 2016.  The transaction, which has been unanimously approved by the Boards of Directors of Citrix and LogMeIn, is expected to be tax-free to Citrix and its shareholders for U.S. federal income tax purposes. The combined company is expected to have annual revenues in excess of $1 billion with more than two million customers in virtually every country around the globe. Upon completion of the transaction, the combined company is expected to achieve run rate cost synergies for the benefit of both Citrix and LogMeIn shareholders of $65 million within the first year post-close, and run rate cost synergies of more than $100 million in year two.

The combination brings together proven innovators with a shared belief in simplifying the way people connect to customers, colleagues and the world around them. The GoTo family of products delivers collaborative communication solutions for small and medium sized businesses and has strong global brand recognition through leading products including GoToAssist, GoToMeeting, GoToMyPC, GoToTraining, GoToWebinar, Grasshopper and OpenVoice.  LogMeIn, a leading provider of cloud-based connectivity, has rapidly attracted millions of users and thousands of leading businesses to its popular and disruptive products, including join.me, LastPass, LogMeIn Rescue and BoldChat, among others.

Bill Wagner, President and CEO of LogMeIn, who will lead the combined company as President and CEO, commented, “We are extremely excited about this transformative merger and the profound benefits it will bring to our customers, our people and our shareholders.  Both companies have passionate employees who are committed to developing easy-to-use software that simplifies the way we connect with people, devices, apps and products.  The additional scale of the combined company will allow us to accelerate innovation in order to deliver better outcomes for our customers and also creates a compelling financial model that will reward our shareholders.”

Kirill Tatarinov, President and Chief Executive Officer of Citrix, said, “We believe this combination is a winning outcome for all parties. Both LogMeIn and GoTo have a shared goal of developing innovative solutions to exceed customer expectations by simplifying business and personal communications. Given that we have already been working towards a spinoff of GoTo, we expect this to be a smooth transition for the business. From Citrix’s perspective, this transaction will allow us to further enhance our strategic focus, operational efficiency and accelerate execution of our strategy to provide the world’s best integrated technology services for secure delivery of apps and data.”

“We have great respect for Bill, the LogMeIn team and the company’s commitment to building great products that simplify how people connect,” said Bob Calderoni, Executive Chairman of Citrix. “When we announced plans to spin off our GoTo family of products last November, we emphasized the value creation opportunity for our shareholders. We believe this combination will accelerate that opportunity, further enhancing value for Citrix shareholders through the ownership of shares in the combined company. I also want to thank Chris Hylen, whose leadership as SVP and GM of the GoTo business, along with the tireless work of his team, has positioned GoTo for continued growth and success following its separation from Citrix.”

Strategic Rationale

• A Leading SaaS Company With A Diverse Product Portfolio – Assets from both companies fill gaps in the respective product lines, resulting in better experiences and outcomes for our customers.  In addition, the scale and stability of the combined company enables accelerated growth of the businesses in emerging verticals, which include cloud-based telephony and identity, as well as IoT.
• A Shared Focus On Innovation That Is Enhanced by Scale – The merger brings together the combined resources of each company to address the challenges customers face in the wake of compelling secular trends, including workforce mobility, rapid adoption of cloud-based applications and the proliferation of connected products.
• Talented Team Positioned To Capture Exciting Growth Opportunities – Through a commitment to retaining the best talent from both companies, the new company will have a seasoned management team with a track record of driving growth, innovation, and shareholder value.  The combined company’s Board will be comprised of experienced directors from both LogMeIn and Citrix who share a commitment to customer satisfaction and shareholder value creation.
• Powerful Financial Profile That Drives Long-Term Shareholder Value – Shareholders are expected to benefit from the significant free cash flow generated as a result of synergy capture, and the scale of the combined company would enable us to take advantage of operational efficiencies over the longer term to continuously improve the company’s financial profile.

Financial Benefits of the Transaction

LogMeIn expects the combined company to have a strong financial profile, including:

• Pro Forma revenue of more than $1 billion
• Pro Forma Adjusted EBITDA margins of approximately 35%, after realizing year one run rate cost synergies of $65 million
• Pro Forma Free cash flow of more than $250 million (after year one run rate cost synergies)
• Anticipated Pro Forma 35%+ Free Cash Flow Accretion over Standalone LogMeIn (after year one run rate cost synergies)

The combined company is expected to achieve run rate cost synergies of more than $100 million within two years post-close.

Management, Governance and Headquarters

LogMeIn’s Bill Wagner will continue in his role as President and CEO, and LogMeIn’s Ed Herdiech will serve as Chief Financial Officer. Certain members of the GoTo management team are expected to join the combined company as well. The combined company will be headquartered in Boston.

Upon closing, the combined company’s Board of Directors will consist of nine directors: five current LogMeIn directors and four Citrix director appointees. Citrix’s four director appointees have proven expertise in driving operational efficiency and will include current Citrix directors Bob Calderoni, Jesse Cohn, and Peter Sacripanti, as well as Citrix’s Chief Operating Officer and Chief Financial Officer, David Henshall. Michael Simon, former CEO and current Chairman of the Board of LogMeIn, will remain in place as Chairman of the combined company’s Board.  Bill Wagner will also retain his Board seat.  LogMeIn’s other three directors will be named at a later date.

The Board will form an Operating Committee upon the close of the transaction, which will consist of two LogMeIn directors and two Citrix directors, all of whom will be named at a later date, to oversee the realization of the full value of the identified synergies. Management and the Operating Committee intend to retain the services of a globally recognized consulting firm to advise on the capture of synergies.

Transaction Details

The combination of LogMeIn and Citrix’s GoTo family of products will be effected through a Reverse Morris Trust (RMT) transaction, pursuant to which Citrix has created a wholly owned subsidiary, or GetGo, to hold the GoTo business.  Citrix will distribute that subsidiary to Citrix shareholders in either a spin-off or split-off transaction. Immediately thereafter, the GetGo subsidiary will be merged with a wholly owned subsidiary of LogMeIn, with GetGo surviving the merger and remaining as a wholly owned subsidiary of LogMeIn. The combination will result in Citrix equityholders receiving an aggregate of approximately 27.6 million LogMeIn shares on a fully diluted basis. Under the RMT structure, the transaction is expected to be tax-free to Citrix and its shareholders for U.S. federal income tax purposes. Immediately following the transaction, Citrix shareholders will own approximately 50.1% of all outstanding shares of the combined company on a fully diluted basis, while existing LogMeIn shareholders will own approximately 49.9% of the combined company on a fully diluted basis.

The issuance of shares by LogMeIn in connection with the transaction requires approval by LogMeIn shareholders, and the transaction is subject to certain regulatory approvals and other customary closing conditions, including receipt of opinions of counsel with respect to the tax-free nature of the proposed transaction.  In connection with the definitive agreement, Michael Simon, LogMeIn’s Chairman of the Board, who currently owns more than 3% of LogMeIn’s shares, has agreed to vote in favor of the transaction. The transaction is expected to close during the first quarter of 2017.

In connection with approving the transaction, on July 26, 2016, LogMeIn’s Board of Directors also declared a special cash dividend of $0.50 per share of common stock.  The special dividend will be paid on August 26, 2016 to shareholders of record on August 8, 2016.  LogMeIn currently has approximately 25.3 million shares of common stock outstanding.   As contemplated by the definitive agreement, the Company announced that it currently expects to declare an additional dividend of $0.50 per share of common stock prior to the consummation of the transaction and a final dividend of $0.50 per share of common stock subject to the consummation of the transaction, on or about the date of such consummation.

Advisors

RBC Capital Markets is serving as financial advisor and Latham & Watkins LLP is serving as legal counsel to LogMeIn. Qatalyst Partners and Goldman, Sachs & Co. are serving as financial advisors to Citrix, and Goodwin Procter LLP and Skadden, Arps, Slate, Meagher & Flom LLP are serving as legal counsel.

Conference Call Details

The two companies will host a joint conference call today at 4:30 p.m. E.T. to discuss this transaction. The call will include a slide presentation and participants are encouraged to view the presentation via webcast at https://investor.logmeininc.com/about-us/investors/overview/default.aspx

The conference call may also be accessed by dialing: (877) 407-9124 (Toll Free) or (201) 689-8584 (International). A replay will be available for approximately 7 days, and can be accessed by dialing: (877) 481-4010 (Toll Free) or (919) 882-2331 (International) and using the ID 10063.

In separate news releases, Citrix and LogMeIn both announced their financial results for the second quarter of 2016, ended June 30, 2016. Immediately following the discussion of the transaction, at 5:15 p.m. E.T., Citrix will discuss its financial results for the second quarter of 2016. LogMeIn will address any questions on earnings on the joint transaction call at 4:30 p.m. E.T. and has cancelled its previously scheduled earnings call set for July 28, 2016.

About LogMeIn

LogMeIn, Inc. (Nasdaq:LOGM) simplifies how people connect to each other and the world around them. With millions of users worldwide, our cloud-based solutions make it possible for people and companies to connect and engage with their workplace, colleagues, customers and products anywhere, anytime. LogMeIn is headquartered in Boston with offices in Bangalore, Budapest, Dublin, London, San Francisco and Sydney.

About Citrix

Citrix (NASDAQ:CTXS) aims to power a world where people, organizations and things are securely connected and accessible to make the extraordinary possible. Its technology makes the world’s apps and data secure and easy to access, empowering people to work anywhere and at any time. Citrix provides a complete and integrated portfolio of Workspace-as-a-Service, application delivery, virtualization, mobility, network delivery and file sharing solutions that enables IT to ensure critical systems are securely available to users via the cloud or on-premise and across any device or platform. With annual revenue in 2015 of $3.28 billion, Citrix solutions are in use by more than 400,000 organizations and over 100 million users globally. Learn more at www.citrix.com.

Forward-Looking Statements

This communication contains “forward-looking statements” concerning LogMeIn, Inc. (“LMI”), Citrix Systems, Inc. (“Citrix”), GetGo, Inc. (“GetGo”), the proposed transactions and other matters. All statements other than statements of historical fact contained in this report are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the current expectations, beliefs and assumptions of the management of LMI, Citrix and GetGo concerning future developments, business conditions, anticipated synergies, pro forma financial results, the Company’s plans to issue dividends in connection with the transaction, and their potential effects. There can be no assurance that future developments affecting the parties will be those that the parties anticipate.

Among the risks and uncertainties that could cause actual results to differ from those described in the forward-looking statements are the following: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, (2) the risk that LMI’s stockholders may not approve the issuance of the Company common stock in connection with the proposed merger, (3) the risk that the necessary regulatory approvals may not be obtained or may be obtained subject to conditions that are not anticipated, (4) risks that any of the closing conditions to the proposed merger, including Citrix’s distribution of the shares of GetGo, may not be satisfied in a timely manner, (5) risks related to disruption of management time from ongoing business operations due to the proposed transactions, (6) failure to realize the estimated synergies or growth from the proposed transactions or that such benefits may take longer to realize than expected, (7) risks related to unanticipated costs of integration of GetGo by LMI, (8) the effect of the announcement of the proposed transactions or the consummation of the proposed transactions on the ability of LMI and Citrix to retain and hire key personnel and maintain relationships with their key business partners and customers, and on their operating results and businesses generally, (9) the length of time necessary to consummate the proposed transactions, (10) adverse trends in economic conditions generally or in the industries in which the LMI and Citrix operate, (11) adverse changes to, or interruptions in, relationships with third parties unrelated to the announcement, (12) LMI’s ability to compete effectively and successfully and to add new products and services, (13) LMI’s ability to successfully manage and integrate acquisitions, (14) the ability to attract new customers and retain existing customers in the manner anticipated, (15)  unanticipated changes relating to competitive factors in the parties’ industries, and (16) the business interruptions in connection with the LMI’s technology systems.  Discussions of additional risks and uncertainties are contained in LMI’s and Citrix’s filings with the U.S. Securities and Exchange Commission (the “SEC”). None of LMI, Citrix or GetGo is under any obligation, and each expressly disclaim any obligation, to update, alter, or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events, or otherwise.  Persons reading this announcement are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof.

No Offer or Solicitation

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.  No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

Important Additional Information Will be Filed with the SEC

In connection with the proposed transaction, LogMeIn and GetGo intend to file registration statements with the SEC. LogMeIn will also file a proxy statement. Citrix stockholders are urged to read the prospectus and/or information statement that will be included in the registration statements and any other relevant documents when they become available, and LogMeIn stockholders are urged to read the proxy statement and any other relevant documents when they become available, because they will contain important information about LogMeIn, GetGo, Citrix and the proposed transactions. The proxy statement, prospectus and/or information statement and other documents relating to the proposed transactions (when they become available) can also be obtained free of charge from the SEC’s website at www.sec.gov. The proxy statement, prospectus and/or information statement and other documents (when they are available) can also be obtained free of charge from Citrix upon written request to Investor Relations, 851 Cypress Creek Road, Fort Lauderdale, FL 33309, or by calling (954) 229-5758 or upon written request to LogMeIn, Investor Relations, 320 Summer Street, Boston, MA 02210 or by calling (781) 897-0694.

Participants in the Solicitation

This communication is not a solicitation of a proxy from any security holder of LogMeIn. However, LogMeIn, Citrix and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from shareholders of LogMeIn in connection with the proposed transaction under the rules of the SEC. Information regarding the persons who are, under the rules of the SEC, participants in the solicitation of the stockholders of LogMeIn in connection with the proposed transactions, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus when it is filed with the SEC.  Information about the directors and executive officers of Citrix may be found in its Annual Report on Form 10-K filed with the SEC on February 18, 2016, and its definitive proxy statement relating to its 2016 Annual Meeting of Shareholders filed with the SEC on April 29, 2016. Information about the directors and executive officers of LogMeIn may be found in its Annual Report on Form 10-K filed with the SEC on February 19, 2016, and its definitive proxy statement relating to its 2016 Annual Meeting of Stockholders filed with the SEC on April 8, 2016.

Contacts

LogMeIn Contacts:
Investors
Rob Bradley
781-897-1301
rbradley@LogMeIn.com 

Press
Craig VerColen
781-897-0696
Press@LogMeIn.com

Citrix Contacts:
Investors
Eduardo Fleites
954-229-5758
eduardo.fleites@citrix.com

Press
Eric Armstrong
954-267-2977
eric.armstrong@citrix.com

$BIND Determines $PFE $40 Million #Bid Optimal

BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that Pfizer Inc. (NYSE: PFE) prevailed at a Section 363 auction to purchase substantially all of BIND’s assets. The winning bid of $40 million, subject to U.S. Bankruptcy Court approval for which a hearing is scheduled to take place on July 27, 2016, was selected as the highest and best bid. NanoCarrier Co., Ltd. has been selected as the back-up bidder. The Company plans to disclose additional terms of its agreement with Pfizer upon Court approval.

BIND initiated voluntary Chapter 11 bankruptcy protection on May 1, 2016 and conducted a sale of assets, pursuant to Section 363 of the Bankruptcy Code, during an auction held on July 25 and 26, 2016.

About BIND Therapeutics
BIND Therapeutics is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer. BIND’S product candidates are based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. BIND is developing ACCURINS® with three different therapeutic objectives, both through internal research programs and with collaborators: Innovative medicines; enabling potent pathway inhibitors; and differentiated efficacy with approved drugs. BIND’s internal discovery efforts are focused on designing oligonucleotide and immune-oncology-based ACCURINS®.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as Merck Sharp & Dohme outside the United States and Canada), Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals), Synergy Pharmaceuticals, PeptiDream and Affilogic to develop ACCURINS® based on their proprietary therapeutic payloads and/or targeting ligands. BIND’s collaboration with AstraZeneca has resulted in the Aurora B Kinase inhibitor Accurin AZD2811, which became the second Accurin candidate to enter clinical development. BIND’s collaboration with Pfizer has resulted in the selection of an Accurin candidate that is entering IND-enabling studies.

For more information, please visit the Company’s web site at www.bindtherapeutics.com.

Forward-Looking Statements Disclaimer
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding disclosing additional terms of the agreement with Pfizer upon court approval; and our collaboration agreements with Pfizer, Merck, AstraZeneca, F. Hoffmann-La Roche Ltd., Macrophage, Synergy, PeptiDream and Affilogic.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: that the Company may not be successful in consummating any of the strategic or financing alternatives it is exploring, including an acquisition by Pfizer, in the timeframe it expects or at all; orders and decisions of the Bankruptcy Court; the fact that the Company has incurred significant losses since its inception and expects to incur losses for the foreseeable future; the Company’s need for additional funding, which may not be available, in order to continue as a going concern; effects of adverse capital market conditions on the Company’s liquidity; any default on the Company’s credit facility, which could impact its ability to continue as a going concern; adverse effects on the Company’s business due to the report of its independent registered public accounting firm on its financial statements for the year ended December 31, 2015, which contains an explanatory paragraph regarding the Company’s ability to continue as a going concern; raising additional capital may cause dilution to its stockholders, restrict its operations or require it to relinquish rights to its technologies or drug candidates; the Company’s limited operating history; limitations on the Company’s ability to utilize net operating loss carryforwards and certain other tax attributes; failure to use and expand its MEDICINAL ENGINEERING® platform to build a pipeline of drug candidates and develop marketable drugs; the early stage of the Company’s development efforts with only BIND-014 and Accurin AZD2811 in clinical development; failure of the Company or its collaborators to successfully develop and commercialize drug candidates; clinical drug development involves a lengthy and expensive process, with an uncertain outcome; delays or difficulties in the enrollment of patients in clinical trials; serious adverse or unacceptable side effects or limited efficacy observed during the development of the Company’s drug candidates; inability to maintain any of the Company’s collaborations, or the failure of these collaborations; inability to enter into a collaboration for BIND-014; the Company’s reliance on third parties to conduct its clinical trials and manufacture its drug candidates; the Company’s inability to obtain required regulatory approvals; the fact that a fast track or breakthrough therapy designation by the FDA for the Company’s drug candidates may not actually lead to a faster development or regulatory review or approval process; the inability to obtain orphan drug exclusivity for drug candidates; failure to obtain marketing approval in international jurisdictions; any post-marketing restrictions or withdrawals from the market; effects of recently enacted and future legislation; failure to comply with environmental, health and safety laws and regulations; failure to achieve market acceptance by physicians, patients, or third-party payors; failure to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities; effects of substantial competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to retain key executives and attract, retain and motivate qualified personnel; difficulties in managing the Company’s growth; risks associated with operating internationally, including the possibility of sanctions with respect to our operations in Russia; the possibility of system failures or security breaches; failure to obtain and maintain patent protection for or otherwise protect our technology and products; effects of patent or other intellectual property lawsuits; the price of our common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company; and any securities class action litigation. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 10, 2016, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

BIND Therapeutics:
Media/Investors
Jeff Boyle, 617-301-8816
jeffboyle@bindtherapeutics.com

$EXPI #RickMiller and #RandallMiles Join @eXpRealty eXp World Holdings Board

$GLNG & #Schlumberger Form #OneLNG #JV #Gas to #LNG

LONDON, July 25, 2016-Golar LNG Limited (“Golar”) and Schlumberger today announced the creation of OneLNG^SM, a joint venture to rapidly develop low cost gas reserves to LNG. The combination of Schlumberger reservoir knowledge, wellbore technologies and production management capabilities, with Golar’s low cost FLNG (Floating LNG) solution, will offer gas resource owners a faster and lower cost development thereby increasing the net present value of the resources.

Golar and Schlumberger have 51/49 ownership of the joint venture. Golar and Schlumberger have agreed an initial investment commitment to cover the estimated equity needed to develop the first project. In addition, the parties will on a project-by-project basis discuss additional debt capital as required. This future financing will take into account Golar’s FLNG intellectual property through an equitable contribution mechanism to be agreed between the parties.

Golar Vice Chairman, Tor Olav Troim said, “Our new venture with Schlumberger provides a powerful union of their oilfield services technology and production management business, and our low cost FLNG solution. It leverages Golar’s LNG expertise, and builds upon our industry leading position as a midstream solutions provider.”

Schlumberger, President Operations, Patrick Schorn commented, “This new joint venture is uniquely positioned to optimize the development of low cost gas reserves. The technology platform and production management capability that Schlumberger brings will enable a total system approach, leading to a simpler and fast-tracked FID process, and reliable operational execution for the benefit of the gas resource owners.”

OneLNG will be the exclusive vehicle for all projects that involve the conversion of natural gas to LNG which require both Schlumberger Production Management services and Golar’s FLNG expertise. After reviewing the current market opportunities where 40% of the world’s gas reserves can be classified as stranded, both parties are excited at the future prospects of OneLNG and are confident that it would conclude 5 projects within the next 5 years.

About Golar LNG

Golar LNG is one of the world’s largest independent owners and operators of LNG carriers with over 30 years of experience. The company developed the world’s first Floating Storage and Regasification Unit (FSRU) projects based on the conversion of existing LNG carriers. Our strategic objective is to become an integrated midstream player in the LNG industry. For more information, visit www.golarlng.com.

About Schlumberger

Schlumberger is the world’s leading provider of technology for reservoir characterization, drilling, production, and processing to the oil and gas industry. Working in more than 85 countries and employing approximately 100,000 people who represent over 140 nationalities, Schlumberger supplies the industry’s most comprehensive range of products and services, from exploration through production, and integrated pore-to-pipeline solutions that optimize hydrocarbon recovery to deliver reservoir performance.

Schlumberger Limited has principal offices in Paris, Houston, London and The Hague, and reported revenues of $35.47 billion in 2015. For more information, visit www.slb.com.

FORWARD LOOKING STATEMENTS

This document includes forward-looking statements regarding the joint venture and the companies, made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  The joint venture and companies’ actual results may differ materially from those described in forward-looking statements.  Such statements are based on current expectations of the joint venture and companies’ performance and are subject to a variety of factors, some of which are not under the control of the joint venture and companies, which can affect the joint venture and companies’ results of operations, liquidity or financial condition.

Because the information herein is based solely on data currently available, it is subject to change as a result of changes in conditions over which the joint venture and companies have no control or influence, and should not therefore be viewed as assurance regarding the joint venture and companies’ future performance.  Additionally, the joint venture and companies are not obligated to make public indication of such changes unless required under applicable disclosure rules and regulations.

For further information, contact:

Brian Tienzo – Golar Management Limited, Chief Financial Officer
Stuart Buchanan – Golar Management Limited, Head of Investor Relations
Tel: +44 207 063 7900

Simon Farrant – Schlumberger Limited, Vice President of Investor Relations
Joy V. Domingo – Schlumberger Limited, Manager of Investor Relations
Tel: +1 713 375 3535
investor-relations@slb.com

Joao Felix – Schlumberger Limited, Director of Corporate Communication
Tel: +1 713 375 3494
communication@slb.com

$VUZI & #APXLabs #SmartGlasses #AR #VR, Industrial #Partner Program

APX Customers to Receive Preview Access of Vuzix M300 Smart Glasses

ROCHESTER, N.Y., July 25, 2016  — Vuzix® Corporation (NASDAQ: VUZI), a leading supplier of Smart- Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets, is pleased to announce that APX Labs, the developer of the Skylight platform, has joined the Vuzix Industrial Partner (VIP) program. Recently recognized by the World Economic Forum as a 2016 Technology Pioneer for its trailblazing work to empower the connected workforce, APX Labs delivers solutions that drive significant business value by unlocking the power of the industrial workforce.  As a Vuzix VIP, APX Labs has received early access to the new Vuzix M300 Smart Glasses to begin showcasing its leading edge capabilities to customers.

This follows the launch earlier this year of Vuzix’ Future Proof offer with APX Labs, which allows customers to begin deployments with APX’s Skylight and Vuzix M100 Smart Glasses and upgrade to the next generation Vuzix M300 seamlessly when the M300 ships to customers later this year. The M300 represents the next generation of smart glasses, designed to address customer feedback from more than two years of productive use of the M100 in the field. The advanced ergonomic design and feature set of the new M300, combined with the latest release of the Skylight software platform, enables enterprise users to operate in an increasing number of scenarios and realize even more complex use cases, while continuing to use the Vuzix M100 as currently deployed within the same software platform.

“Vuzix’s focus on the enterprise customer shines in the M300 Smart Glasses,” said Brian Ballard, Chief Executive Officer at APX Labs. “Our Skylight platform has been waiting for the capabilities and flexibility of the M300. It will allow customers to scale their smart glasses deployments faster and see a more immediate return on investment. This really is exciting for us and for the industry at large.”

“We are pleased to continue working very closely with APX Labs,” said Paul Travers, President and Chief Executive Officer of Vuzix. “Skylight is one of the “best in class” enterprise solutions available and provides a great platform for our M300 to be transformative for industrial businesses across a range of applications.”

To learn more about how Vuzix M300 and the APX Skylight platform work together, visit: https://www.apx-labs.com/vuzix-m300.  To learn more about the M300, or becoming a VIP, please contact Lance Anderson, VP of Enterprise Sales, at lance_anderson@vuzix.com.

About APX Labs
Since 2010, APX Labs has been pioneering the application of wearable technology for the hands-on workforce. APX Labs’ Skylight software product leverages wearable devices, like the Vuzix M100 and soon the M300, integrates with existing business systems, and is used today in a wide range of industrial operations including manufacturing, field service, repair, training, material handling, and compliance. Customers include Boeing, GE, Rio Tinto, ExxonMobil, Jabil, Merck, Shell, Johnson & Johnson, Baker Hughes, Applied Materials and Westinghouse. For additional information, visit www.apx-labs.com.

About Vuzix Corporation
Vuzix is a leading supplier of Smart Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets. The Company’s products include personal display and wearable computing devices that offer users a portable high quality viewing experience, provide solutions for mobility, wearable displays and virtual and augmented reality. Vuzix holds 40 patents and 23 additional patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2014 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Rochester, NY, Oxford, UK and Tokyo, Japan.

Forward-Looking Statements Disclaimer
Certain statements contained in this news release are “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward looking statements contained in this release relate to, among other things, and the Company’s leadership in the Video Eyewear, VR and AR display industry and our relationship with APX Labs the its potential in the industrial markets. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Investor and Media Relations Contact:

Andrew Haag
Managing Partner
IRTH Communications
vuzi@irthcommunications.com
1-866-976-4784

Vuzix Corporation
25 Hendrix Road, Suite A West
Henrietta, NY 14586 USA
Investor Information – Grant Russell IR@Vuzix.com
Tel: (585) 359-7562 www.vuzix.com

For further sales, and product information, please visit:

North America:
http://www.vuzix.com/contact/

Europe/UK:
https://www.vuzix.eu/contact/

Asia:
http://www.vuzix.jp/contact.html

$AMD Selected by #Sammy Corp. #Pachinko #Pachislot for new #3D #Gaming Machine

Sammy Corporation Adopts AMD Embedded R-Series APU for Pachislot

SUNNYVALE, CA–(Jul 25, 2016) –  AMD (NASDAQ: AMD) today announced that Sammy Corporation in Japan is using the AMD Embedded R-Series APU for its new pachislot machine, named “Pachislot Hokuto no Ken: Shura no Kuni.” Much like other gaming options, pachislot systems are increasingly compute intensive and graphically immersive, requiring high performance 3D graphics for the modern game player. Sammy has announced that the new machine is expected to launch in pachislot parlors across Japan beginning in fall, 2016.

The strong visual element and growing need for quality graphics in gaming machines are an ideal match for AMD Embedded R-Series processors that combine high performance x86 CPUs and with leading graphics capabilities.

“Gaming is a natural application of our APU technology that combines strong compute with high performance and stunning graphics,” said Stephen Turnbull, director of embedded vertical industry marketing, AMD Enterprise Solutions. “Our collaboration with Sammy Corporation has enabled the development of a pachinko slot machine which employs real 3D video technology in an industry that traditionally employs 2D imagery. The energy-efficient AMD Embedded R-Series processors help Sammy to create amazing visual experiences for their customers.”

Supporting Resources

• Learn more about the new AMD Embedded R-Series product family
• AMD Embedded Processor product page
• Follow @AMDEmbedded on Twitter
• Become a fan of AMD on Facebook
• Follow AMD on Twitter @AMD

About AMD
For more than 45 years AMD has driven innovation in high-performance computing, graphics and visualization technologies — the building blocks for gaming, immersive platforms and the datacenter. Hundreds of millions of consumers, leading Fortune 500 businesses and cutting-edge scientific research facilities around the world rely on AMD technology daily to improve how they live, work and play. AMD employees around the world are focused on building great products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, and Facebook and Twitter pages.

$ZSAN First Subject Treated, Pivotal #Efficacy #Trial for #M207 in Acute #Migraine

FREMONT, Calif., July 25, 2016  — Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’s proprietary transdermal delivery system, today announced the dosing of its first subject in its registration-enabling pivotal efficacy trial (the Zotrip trial), of its M207 patch, formerly known as ZP-Triptan, for the treatment of acute migraine.

“I’m extremely pleased to announce our first subject treated in the Zotrip trial.  We are pleased with enrollment to date and reiterate that trial results are expected to be reported in the first quarter of 2017,” commented Konstantinos Alataris, PhD, President and Chief Executive Officer of Zosano Pharma. To date, 136 subjects have enrolled in the trial, 109 of which are in the run-in phase, and 7 subjects have been randomized.

M207 is Zosano’s proprietary zolmitriptan-coated microneedle patch that is designed to rapidly deliver zolmitriptan during a migraine attack. In a recently completed phase I trial, M207 demonstrated markedly faster absorption kinetics compared to oral zolmitriptan.  The Company recently presented these results at the 2016 annual meeting of the American Headache Society. The Company believes M207’s injection-free mode of delivery has the potential to provide an attractive solution for acute migraine sufferers.

The ongoing Zotrip trial is a multicenter, double-blind, randomized, placebo-controlled trial comparing three doses of M207 (1.0 mg, 1.9 mg, and 3.8 mg) to placebo for the treatment of a single migraine attack. Three hundred sixty subjects are expected to be treated in the Zotrip trial at approximately 35 centers across the United States. Subjects are recruited into the Zotrip trial if they have a history of at least one year of episodic, acute migraines with or without aura. Upon recruitment, subjects undergo a screening and run-in period to ensure they meet the key eligibility criterion of 2-8 migraine attacks per month, documented using an electronic diary. Successfully screened subjects are then randomized into the treatment/dosing period and have 8 weeks to confirm and receive blinded treatment for a single migraine attack. Today’s announcement marks the commencement of the dosing/treatment phase of the Zotrip trial.

Based on the Company’s discussions with the FDA and the FDA’s October 2014 Draft Guidance–“Migraine:  Developing Drugs for Acute Treatment,” the co-primary endpoints of this study are:

(i) pain freedom at 2 hours post-dosing, and
(ii) freedom from each subject’s most bothersome symptom at 2 hours post-dosing.

Furthermore, the FDA has indicated that a single, positive, pivotal efficacy study, in addition to a safety study, will be sufficient for approval under the 505(b)(2) pathway. The Company intends to conduct the safety study after completion of the Zotrip trial.

About Zosano Pharma

Zosano Pharma Corporation is an emerging CNS company focusing on providing rapid symptom relief to patients using known therapeutics and altering their delivery profile using the Company’s proprietary transdermal delivery system. The Company’s goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action. Zosano Pharma has developed its proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.  The Company believes that its transdermal delivery system offers rapid and consistent drug delivery combined with ease of use.  The Company is focused on developing products that deliver established molecules with known safety and efficacy profiles for markets where patients remain underserved by existing therapies.  Zosano Pharma anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, including the timeline for pivotal efficacy data, our ability to obtain necessary regulatory approvals and other future events and expectations. Readers are urged to consider statements that include the words “expects,” “continues,” “believes,” “potential,” “goal,” “may,” “will,” “would,” “could,” “should,” “might,” “estimates,” “projects,” “plans,” “anticipates,” “intends,” “forecast,” “designed,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading “Risk Factors” in our 2015 Annual Report on Form 10-K, as filed with the Securities Exchange Commission on March 29, 2016. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
Konstantinos Alataris, Ph.D.
Chief Executive Officer
510-745-1200

Investor Contact:
Jamien Jones
Blueprint Life Science Group
415-375-3340 x 5
jjones@bplifescience.com

OR

Patti Bank
Westwicke Partners
415-513-1284
patti.bank@westwicke.com

$JAGX Positive Preliminary #Topline #Results, #Neonorm Botanical Extract

High resolution in treated animals versus high mortality in control piglets, 1-3 days old Jaguar has entered into negotiations for a potential exclusive distribution relationship for pigs and dairy cattle in the Chinese marketplace with the China-based business entity involved in conducting these studies

SAN FRANCISCO, July 25, 2016  — Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced positive topline results of two recently-completed studies to evaluate the safety and effectiveness of Neonorm^™ botanical extract (“Neonorm^™“) in piglets. The studies were sponsored by a Chinese business entity and took place at pig farms in China.

The initial study, which took place from March to May of 2016, was a multi-site study, involving 433 piglets, from two age groups (1-3 days and 10-15 days), that had a history of diarrhea. The piglets were either placed in a treatment group in which they were individually treated with 10-20 mg of Neonorm^™ powder in a water formulation twice daily for three days or placed in a control group.

In the groups of piglets aged 1-3 days, 99% achieved resolution of diarrhea following Neonorm^™ treatment versus no resolution in the control group. There was a 3% mortality in the Neonorm^™ group, while the control group had 100% mortality. In the group of piglets aged 10-15 days, the rate of diarrhea resolution was 70%, versus no resolution in the control group; mortality was 30% versus 100%, respectively. Comparisons of diarrhea resolution and mortality rates between the Neonorm^™-treated group and control groups generated p-values less than 0.01.

The second study was initiated in June of this year at a farm in China that had just experienced an outbreak of Porcine Epidemic Diarrhea Virus (PEDv). Piglets at this farm were divided into three treatment groups with no control and received 8-20 mg of Neonorm^™. The 200 piglets placed in treatment group A were all suffering from diarrhea caused by PEDv. The 200 piglets in treatment group B had recently contracted PEDv, and received a lower dose of Neonorm^™.  The 100 piglets in treatment group C were healthy and were treated prophylactically.

The results of the second study demonstrate a 95% cure rate among piglets in group A, who received 10-20 mg of Neonorm^™ administered over two days. The cure rate in group B among piglets that received 8-16 mg of Neonorm^™ for three days was 60%. At this farm, a mortality rate of 50% is typically seen in piglets diagnosed with PEDv. Group C was treated prophylactically with 8-16 mg of Neonorm^™ for three days and 15% developed diarrheal symptoms, which is similar to the usual frequency at this farm without prophylactic treatment.

“We are very encouraged by these preliminary results. As the most common disease in newborn pigs¹, diarrhea has a significant impact on the global swine market as well as food security,” stated Lisa Conte, Jaguar’s president and CEO.

Jaguar has entered into negotiations for a potential exclusive distribution relationship for pigs and dairy cattle in the Chinese marketplace with the China-based business entity that was involved in conducting these studies.

According to the U.S. Department of Agriculture’s (USDA) National Veterinary Services Laboratories, PEDv’s pathogenic agent is a coronavirus, and PEDv is most serious in neonatal piglets, where morbidity and mortality can be 80 to 100 percent. The coronavirus infects the cells lining the small intestine of a pig, causing porcine epidemic diarrhea (PED), a condition of severe diarrhea and dehydration. The USDA confirmed the first PED diagnosis in the United States on May 17, 2013 in Iowa.

PED can lead to significant economic loss in the swine industry because of the high morbidity and mortality that occurs in immunologically naïve neonatal piglets, according to the USDA. Vaccination and increased biosecurity needs related to PED further increase production costs², and, per the USDA, there is currently no effective treatment against PED other than control of secondary infections.

According to the Minnesota-based Institute for Agriculture and Trade Policy, swine production was expected to reach 723 million head in 2014 in China, where pork is still the main protein source for many consumers. In 2011, U.S. agriculture produced 110.9 million hogs, according to the American Meat Institute. Pork products constitute the second largest segment of U.S. meat and poultry production, which is in itself the largest segment of U.S. agriculture. In 2011, the U.S. exported 1.75 billion metric tons of pork and related products worth $5.32 billion, according to the American Meat Institute.

About Neonorm^™
Neonorm^™ is a standardized botanical extract derived from the Croton lechleri tree, which is sustainably harvested. Neonorm^™ Calf and Neonorm^™ Foal are the Company’s lead non-prescription products. Jaguar intends to develop species-specific formulations of Neonorm^™ in six additional target species.

About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia^™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. SB-300 is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia^™ and SB-300 contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm^™ Calf and Neonorm^™ Foal are the Company’s lead non-prescription products. Neonorm^™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia^™ and Neonorm^™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm^™ in six additional target species, formulations of SB-300 in horses, and Canalevia^™ for cats and dogs.

For more information, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding a potential exclusive distribution relationship for pigs and dairy cattle in the Chinese marketplace between Jaguar and the China-based business entity involved in conducting these studies, the Company’s intention to develop formulations of SB-300 in horses and species-specific formulations of Neonorm^™ in additional target species, and the Company’s plan to develop formulations of Canalevia^™ for cats and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

$BLPH Approval to Commence #Phase2 Trial in Pulmonary #Hypertension #COPD

— Trial expected to commence in third quarter; Results to be reported by year end 2016 —
— Previous data supporting testing long-term benefits of pulsed inhaled nitric oxide (iNO) reported in peer-reviewed International Journal of COPD —

WARREN, N.J., July 25, 2016 — Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced it has received health authority approval in Belgium to commence a Phase 2 trial for INOpulse, its patented and proprietary pulsatile nitric oxide [NO] delivery device, to treat pulmonary hypertension in chronic obstructive pulmonary disease, or PH-COPD. This follows results from the Company’s Phase 2a study and proof of mechanism work, which indicated that INOpulse could be both safe and effective in PH-COPD. Bellerophon expects to enroll the first patient in the third quarter of 2016 with results of the trial expected before year end.

Approximately 12 million people in the United States suffer from COPD of which approximately 700,000 are PH-COPD patients. Severe COPD is often associated with secondary pulmonary hypertension, which worsens its prognosis, is associated with high hospitalization rates, impaired exercise capacity and carries with it a median life expectancy of four years. Earlier Phase 2a data showed that in an acute setting, Bellerophon’s INOpulse safely reduced PH for COPD patients and increased blood volume in the vessels within the lung.

Trial Protocol

The Phase 2 study of INOpulse for PH-COPD is designed to demonstrate the potential benefit of INOpulse on exercise capacity for patients suffering from PH-COPD and will enroll 10 COPD patients with PH on LTOT. The trial is an open-label study of iNO 30 mcg/kg IBW (Ideal Body Weight)/hour for four weeks with a follow up visit two weeks after discontinuation of iNO.  After four weeks of treatment, patients’ vasodilation in pulmonary arteries will be measured by high resolution CT scanning (HRCT), with a key secondary endpoint of 6MWD at four weeks.

“This study builds on the results of earlier work by the Vonbank group in Austria, our own Phase 2a acute dose ranging study as well as the results of a trial conducted in the Department of Respiratory Medicine at the University Hospital Antwerp, by Professor Wilfried De Backer and Bellerophon, published in the peer-reviewed International Journal of COPD (Hajian et al., Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension, International Journal of COPD, 2016, 11:1533-1541),” stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics.

“The prognosis of COPD patients with severe PH is very poor and there is currently no approved therapy to treat this condition. We look forward to developing a therapy for this serious unmet medical need and reporting results by year end 2016,” concluded Mr. Peacock.

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse platform, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF). The Company’s plans also call for the completion of further work on the use of INOpulse to treat PH-COPD and PH-IPF during 2016.  For more information, please visit www.bellerophon.com.

Forward-looking Statements

Any statements in this press release about Bellerophon’s future expectations, plans and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company’s clinical trials and expectations regarding the sufficiency of the Company’s cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary or interim results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, the FDA’s substantial discretion in the approval process, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of the Company’s most recent filings with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent Bellerophon’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Contacts
At Bellerophon:
Fabian Tenenbaum, Chief Financial Officer
(908) 574-4767

At Rx Communications Group:
Melody Carey
(917) 322-2571

$VDSI Expands Relationship w/ #Mobile #App #Security Dev. #Promon

Runtime Application Self-Protection Technology (RASP) protects mobile applications from the newest and most advanced malware threats

OAKBROOK TERRACE, Ill., July 22, 2016  — VASCO Data Security International, Inc. (NASDAQ:VDSI), a global leader in authentication, electronic signatures, and identity management announced today that it has made a strategic investment in Promon AS, a leading developer of mobile application security solutions. This expands an existing business relationship between VASCO and Promon AS. The companies will continue to collaborate in the development of mobile application security solutions.

Promon is a leader in Runtime Application Self-Protection (RASP) technology, a security technology integrated into the application environment capable of detecting and preventing real-time attacks against mobile applications. Its patented deep protection technology, Promon SHIELD™, has protected applications used by millions since 2009. By integrating Promon’s RASP technology, VASCO enhances its ability to help businesses in all market segments protect their mobile applications from hacking attacks.

“With this investment and the expansion of our partnership with Promon, VASCO solidifies its position as a leader in mobile application protection,” said Scott Clements, EVP and Chief Strategy Officer of VASCO Data Security. “Our customers rely on us to bring them the most advanced mobile security solutions in a complete and easy to deploy package.”

Promon SHIELD technology is a component of VASCO’s DIGIPASS for Apps mobile security platform offering advanced protection against hacker attacks. DIGIPASS for Apps is a software development kit (SDK) that allows mobile application developers to quickly and easily integrate the most advanced application security features into their mobile applications.

“We are delighted to have VASCO as a partner and investor given its deep experience and leadership in mobile security for financial institutions,” commented Gustaf Sahlman, CEO of Promon AS. “The new capital will be used to further develop our world-class app hardening technology and to accelerate international growth in vertical markets where app integrity is of critical importance.”

About Promon
Promon’s proprietary technology Promon SHIELD™ represents a new generation of app hardening technologies, which secures apps from both known and unknown attack vectors. Promon protects applications and apps used by millions of users in areas where customer and data integrity is of key importance. Promon is headquartered in Oslo, Norway, with sales offices in Germany and the UK. Promon has an OEM program, which allows partners to provide Promon as part of their own solutions. Additional information about Promon may be found at promon.co.

About VASCO
VASCO is a world leader in providing two-factor authentication and digital signature solutions to financial institutions. More than half of the top 100 global banks rely on VASCO solutions to enhance security, protect mobile applications and meet regulatory requirements. VASCO also secures access to data and applications in enterprise environments, and provides tools for application developers to easily integrate security functions into their web-based and mobile applications. VASCO enables more than 10,000 customers in 100 countries to secure access, manage identities, verify transactions, electronically sign documents and protect assets across financial, enterprise, E-commerce, government and healthcare markets. Learn more about VASCO at VASCO.com and on Twitter, LinkedIn and Facebook.

Copyright © 2016 VASCO Data Security, Inc., VASCO Data Security International GmbH. All rights reserved. VASCO® is a registered or unregistered trademarks of VASCO Data Security, Inc. and/or VASCO Data Security International GmbH in the U.S. and other countries.

Forward Looking Statements: 
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, including, without limitation the guidance for full year 2016. These forward-looking statements (1) are identified by use of terms and phrases such as “expect”, “believe”, “will”, “anticipate”, “emerging”, “intend”, “plan”, “could”, “may”, “estimate”, “should”, “objective”, “goal”, “possible”, “potential”, “project” and similar words and expressions, but such words and phrases are not the exclusive means of identifying them, and (2) are subject to risks and uncertainties and represent our present expectations or beliefs concerning future events. VASCO cautions that the forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These risks, uncertainties and other factors have been described in our Annual Report on Form 10-K for the year ended December 31, 2015 and include, but are not limited to, (a) risks of general market conditions, including currency fluctuations and the uncertainties resulting from turmoil in world economic and financial markets, (b) risks inherent to the computer and network security industry, including rapidly changing technology, evolving industry standards, increasingly sophisticated hacking attempts, increasing numbers of patent infringement claims, changes in customer requirements, price competitive bidding, and changing government regulations, and (c) risks specific to VASCO, including demand for our products and services, competition from more established firms and others, pressures on price levels and our historical dependence on relatively few products, certain suppliers and certain key customers. Except for our ongoing obligations to disclose material information as required by the U.S. federal securities laws, we do not have any obligations or intention to release publicly any revisions to any forward-looking statements to reflect events or circumstances in the future or to reflect the occurrence of unanticipated events.

VASCO Data Security Contact:
Corporate Communications: 
+1-847-370-1486 (US) or +32 2 609 97 00 (ROW) 
pr@vasco.com

$DXCM #FDA Allows #DexCom G5 Mobile #CGM System #NonAdjunctive Label

Conference call scheduled for 8:30AM ET

SAN DIEGO, July 22, 2016  — DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that the Clinical Chemistry and Clinical Toxicology Devices Panel of the U.S. Food and Drug Administration (FDA) voted in favor of the proposed non-adjunctive indication for the DexCom G5 Mobile CGM system. This indication would designate the G5 Mobile CGM system as a replacement to fingerstick glucose testing for diabetes treatment decisions.

Specifically, the panel voted:

• 8-2 supporting that there is reasonable assurance that the DexCom G5 Mobile CGM system is safe for the proposed indications for use,
• 9-1 supporting that there is reasonable assurance that the DexCom G5 Mobile CGM system is effective for the proposed indications for use, and
• 8-2 supporting that the benefits of the DexCom G5 Mobile CGM system outweigh the risks for the proposed indications for use.

“This recommendation is a big milestone for people with diabetes,” said Kevin Sayer, DexCom President and Chief Executive Officer. “The diabetes community turned out in force to support this decision. We commend the FDA for bringing this important subject into a public forum, and thank the panel members, as well as the public speakers for their willingness to participate. We look forward to continued positive discussions with the FDA as we seek the agency’s approval of our application.”

Conference Call

DexCom management will hold a conference call to discuss the meeting starting at 8:30 a.m. (Eastern Time) today, Friday, July 22.

To listen to the conference call, please dial (888) 771-4371 (US/Canada) or (847) 585-4405 (International) and use the confirmation number “43019542” approximately five minutes prior to the start time.

The conference call will be concurrently webcast.  The link to the webcast will be available on the DexCom, Inc. website here.

About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients.  With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information on the DexCom CGM, visit www.dexcom.com.

CONSUMER CONTACT:
Caren Begun, 201-396-8551

INVESTOR CONTACT:
Steve Pacelli, 858-200-0200

$LION Declares #Q3 #Cash #Dividend

ATLANTA, July 22, 2016  — Fidelity Southern Corporation (NASDAQ: LION) announced that the Corporation has declared a quarterly cash dividend of $.12 per share on its Common Stock.  This dividend is payable August 15, 2016, to shareholders of record on August 2, 2016.

Fidelity Southern Corporation, through its operating subsidiaries Fidelity Bank and LionMark Insurance Company, provides banking services and trust and wealth management services and credit-related insurance products through branches in Georgia and Florida, and an insurance office in Atlanta, Georgia.  SBA, indirect automobile, and mortgage loans are provided throughout the South.  For additional information about Fidelity’s products and services, please visit the web site at www.FidelitySouthern.com.